

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/36447 A2


- (51) International Patent Classification⁷: C07K
- (21) International Application Number: PCT/US00/41224
- (22) International Filing Date: 17 October 2000 (17.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/421,971 20 October 1999 (20.10.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/421,971 (CON)
Filed on 20 October 1999 (20.10.1999)
- (71) Applicant (for all designated States except US): THE SALK INSTITUTE FOR BIOLOGICAL STUDIES [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): GAGE, Fred, H. [US/US]; 6668 Caminito Hermitage, La Jolla, CA 92037 (US). SUHR, Steven, T. [US/US]; 8860 Via La Jolla Drive, La Jolla, CA 92037 (US). GIL, Elad, B. [US/US]; 141 Charles St. #3, Boston, MA 02114 (US). SENU, Marie-Claude, C. [US/US]; 8860 Via La Jolla Drive, La Jolla, CA 92121-2189 (US).
- (74) Agent: REITER, Stephen, E.; Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: HORMONE RECEPTOR FUNCTIONAL ENTITIES AND METHODS OF THEIR USE

R/U(N)E [D] [L] [D] [L]

E(N)R/U [D] [L] [D] [L]



(57) Abstract: The invention provides chimeric proteins having at least two functional protein units, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily. The chimeric proteins can fold under crystallization conditions to form functional entities. The functional entities optionally contain a novel flexible peptide linker of variable lengths between at least two of the protein units. In a preferred embodiment, the linker is designed to be increased in increments of 12 amino acids each to aid in preparation of variant chimeric proteins. The DNA binding characteristics of the invention functional entities differ from those of wild-type complexes formed between "monomeric" receptors and their binding partners. Some functional entities, e.g. dimers expressed as fusion proteins, transactivate responsive promoters in a manner similar to wild-type complexes, while others do not promote transactivation and function instead essentially as constitutive repressors. The invention further provides nucleotide sequences encoding the invention chimeric proteins, cells containing such nucleotide sequences, and methods for using the invention chimeric proteins to modulate expression of one or more exogenous genes in a subject organism. In addition, isolated protein crystals suitable for x-ray diffraction analysis and methods for obtaining putative ligands for the invention chimeric proteins are provided.

WO 01/36447 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

- Without international search report and to be republished upon receipt of that report.

HORMONE RECEPTOR FUNCTIONAL ENTITIES AND METHODS OF THEIR USE

FIELD OF THE INVENTION

The present invention relates to methods in the field of recombinant DNA technology, and products related thereto. In a particular aspect, the invention relates to methods for modulating the expression of exogenous genes in mammalian or non-mammalian systems, and products useful therefor.

BACKGROUND OF THE INVENTION

It is known in the art to produce fusion proteins for a number of purposes. In some cases, the two protein units in the single polypeptide have two essentially independent activities. The most common example of this application is the fusion of marking proteins, such as GFP, to intracellular factors as a means of observing their localization and expression (see, for example, A.W. Kerrebrock *et al.*, *Cell*, 83:247-56, 1995; H.G. Wang *et al.*, *Cell*, 87:629-638, 1996). Creation of fusion proteins has also been used to prolong the half-life of a protein (see, for example, R.A. Hallewell, *et al.*, *J. Biol. Chem.*, 264:5260-5268, 1989; T.P. Yao *et al.*, *Cell*, 71:6372, 1992) as well as other uses (see, for example, T. Sano *et al.*, *Proc Natl Acad Sci U.S.A.*, 89:1534-1538, 1992).

A more complicated application of protein fusion is the production of fusion proteins wherein the two protein units cooperate to achieve a biological function. In functional dimers, both proteins must fold and interact with each other appropriately. V.A. Garcia-Campayo *et al.* (*Nature Biotech.*, 15:663-667, (1997)) have utilized a peptide linker to fuse gene subunits together into a single biologically active peptide. Neuhold and Wold, (*Cell*, 74:1033-1042, (1993)) have reported the fusion of two proteins into a single biologically active protein that binds DNA targets, wherein the protein units interact with each other to the exclusion of competing heterodimer partners. However, fusion of proteins with multiple functions has been more difficult to produce, for example, steroid/thyroid hormone nuclear receptors are complex, multifunctional proteins with, minimally, four interconnected yet separable functions: ligand binding, dimerization, DNA binding, and transactivation.

Steroid/thyroid hormone nuclear receptors are used in the field of genetic engineering as a tool for studying control of gene expression and to manipulate and control development and other physiological processes. For example, applications for regulated gene expression in mammalian systems include inducible gene targeting, overexpression of toxic and teratogenic genes, anti-sense RNA expression, and gene therapy (see, for example, R. Jaenisch, *Science* 240:1468-1474, 1988). For cultured cells, glucocorticoids and other steroids have been used to induce the expression of a desired gene.

As another means for controlling gene expression in mammalian systems, an inducible tetracycline regulated system has been devised and utilized in transgenic mice, whereby gene activity is induced in the absence of tetracycline and repressed in its presence (see, e.g. Gossen *et al.* *PNAS* 89:5547-5551, 1992; Gossen *et al.*, *TIBS* 18:471-475, 1993; Furth *et al.*, *PNAS* 91:9302-9306, 1994; and Shockett *et al.*, *PNAS* 92:6522-6526, 1995). However, disadvantages of the inducible tetracycline

system include the requirement for continuous administration of tetracycline to repress expression and the slow clearance of antibiotic from bone, a side-effect that interferes with regulation of gene expression. While this system has been improved by the recent identification of a mutant tetracycline repressor that acts conversely as an inducible activator, the pharmacokinetics of tetracycline may hinder its use during development when a precise and efficient "on-off" switch is essential (see, e.g., Gossen *et al.*, *Science* **268**:1766-1769, 1995).

Certain insect steroid/thyroid hormone nuclear receptors have also been studied. The *Drosophila melanogaster* ecdysone receptor (EcR) (M. R. Koelle *et al.*, *Cell* **67**:59-77, 1995) is unlike the estrogen, androgen, and other homodimeric vertebrate steroid hormone nuclear receptors because it requires a heterologous dimer partner for functional transactivation. The obligate dimer partner, the product of the *ultraspiracle* (Usp) gene (V. C. Henrich *et al.*, *Nuc. Acids Res.* **18**: 4143-4148, 1990; T. P. Yao *et al.*, *supra*, 1992; T. P. Yao *et al.*, *Nature* **366**:476-479, 1993), is an insect homolog of the mammalian retinoid X receptor (RXR) proteins found in vertebrates and other mammalian species. RXRs have been characterized as regulatory dimer partners of many mammalian class II steroid/thyroid hormone nuclear receptors, such as the thyroid hormone receptors, the retinoic acid receptors, and the vitamin D receptor (reviewed in Mangelsdorf and Evans, *Cell* **83**:841-850, 1995; D. J. Mangelsdorf *et al.*, *Cell* **83**: 835-839, 1995). RXR is also a dimer partner of EcR.

Usp and RXR share a significant degree of sequence homology and some functional similarities; however, in formation of heterodimers with EcR, RXR interacts differently than Usp. One primary difference is that formation of EcR+RXR heterodimers is more highly stimulated by the steroid ligand ecdysteroid muristerone A (murA) than by 20-hydroxyecdysone (20-Ec), while formation of EcR+Usp heterodimers is potently stimulated by 20-hydroxyecdysone (K. S. Christopherson *et al.*, *Proc Natl Acad Sci U S A* **89**:6314-6318, 1992; H. E. Thomas *et al.*, *Nature* **362**:471-475, 1993). A second difference is in the way that ligand promotes efficient formation of EcR+Usp and EcR+RXR heterodimer complexes and concomitant binding to ecdysone response elements (EcREs). MurA stimulates EcR+Usp binding of EcREs approximately 3 to 7-fold over levels without ligand, but EcR+RXR complexes are completely dependent on ligand for heterodimerization. Further EcR+RXR complexes bind to EcREs at only 10-40% the level of EcR+Usp complexes (Christopherson *et al.*, *supra* 1992; Thomas *et al.*, *supra* 1993; Yao *et al.*, *supra*, 1992 & 1993). This suggests that the affinity of EcR for its natural dimer partner, Usp, is significantly greater than its affinity for RXR.

EcR has been studied for use in transgene regulation; however, its use for this purpose is complicated by the requirement for superphysiological levels of RXR protein to be coexpressed (No *et al.*, *supra* 1997), presumably because of the comparatively low affinity of EcR for RXR as a dimer partner. Of the mammalian cell types heretofore examined, only the 293 cell line appears capable of supporting high level transactivation of EcR without added RXR (Christopherson *et al.*, *supra*, 1992). The requirement for co-expression of RXR in most mammalian systems raises concerns that RXR will heterodimerize with endogenous mammalian class II steroid/thyroid hormone nuclear receptors, causing altered differentiation, growth, or fitness of transduced cells.

A number of ecdysone receptors are known in the art as being a gene sequence responsive to an applied exogenous chemical inducer enabling external control of expression of the gene controlled by the receptor (See, for example, PCT/GB96/01195).

Accordingly, there is a need in the art for improved systems to precisely modulate the expression of exogenous genes in mammalian subjects. For example, a non-mammalian-based transcription regulating system would be extremely desirable for general application to transgene regulation in *in vitro*, *ex vivo*, and *in vivo* applications. In addition, there is a need in the art for new and better methods of using steroid/thyroid hormone nuclear receptors that require a dimer partner for functional transactivation of transgene expression for use in somatic gene therapy and for laboratory models thereof.

BRIEF DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided chimeric proteins comprising at least two functional protein units, wherein each functional protein unit comprises the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, and an optional linker interposed therebetween, wherein the at least two protein units form a functional entity. When the chimeric protein contains two functional protein units, the chimeric protein forms a functional dimer (FD), for example a heterodimer or a homodimer. In one embodiment according to the present invention, each protein unit comprises a ligand binding domain and an optional hinge domain of a steroid/thyroid hormone nuclear receptor member, and an optional DNA binding domain. The functionality of the entity is independent of the order of the protein units in the chimeric protein. Polynucleotides encoding the invention chimeric protein and cells containing such polynucleotide(s) are also provided according to the present invention. In one embodiment according to the present invention, the invention polynucleotide encodes the invention chimeric protein as a fusion protein, with one or more linker(s) encoded as a polypeptide linker.

In accordance with another embodiment of the present invention, there are provided methods for modulating the expression of exogenous gene(s) in a subject organism containing DNA construct(s) encoding and expressing invention chimeric protein(s) and DNA construct(s) encoding and expressing exogenous gene(s) under the control of a response element. The invention method for modulating the expression of exogenous gene(s) in a subject organism comprises administering to the subject an effective amount of an exogenous ligand for at least one functional unit of the chimeric protein.

The present DNA binding studies indicate that many of the invention functional dimers (FDs) display DNA binding equivalent or superior to that of receptor complexes formed from and/or containing identical wild type members of the steroid/thyroid hormone nuclear receptor superfamily (i.e., the same two members from which the invention chimeric protein is derived). Transient transfection analysis reveals that distinct groups of FD constructs transactivate responsive promoters in a manner similar to wild-type complexes, while others lose the capacity to transactivate and function like constitutive repressors.

Competition experiments and supporting data reveal that FDs favor dimerization with dimer partners contained within a chimeric protein over interaction with other wild type dimer partners. These results demonstrate that certain of the invention chimeric protein FDs share properties of monomeric receptor complexes while others have novel characteristics unique to individual constructs.

5 To enhance the possibility of producing a functional entity upon expression, the invention chimeric proteins allow for any of the protein units to be positioned at the amino terminus of the chimeric protein. In addition, to enhance flexibility for proper folding and three-dimensional orientation of the protein units into a functional entity, an optional linker can be interposed between the protein units in the chimeric protein. A variety of different linkers can be used in the invention chimeric proteins, including chemical and polypeptide linkers, with the latter being preferred if the entity is expressed as a fusion protein. In a presently preferred embodiment, the linker is designed to allow for incremental elongation of the linker distance interposed between the two protein units.

BRIEF DESCRIPTION OF THE FIGURES

In the interests of brevity and consistency, the names of receptors and dimer partners have been abbreviated for use herein as follows: "E", "U", or "R" alone indicates a monomeric receptor protein or dimer partner (i.e., not contained in an invention chimeric protein) containing, respectively, at least the ligand binding domain of the *Drosophila* ecdysone receptor, the *ultraspiracle* protein, or the retinoid X receptor. When contained within an invention "fusion protein", which is alternatively referred to herein as a "functional dimer", these receptor proteins are represented by "E", "U", or "R" separated by either an "N", representing a linker of any length, or a numeral from 0 to 20, indicative of a linker containing a specific number of linker segments wherein each linker segment contains 12 amino acids. In the description of invention fusion proteins, which are functional dimers, the leading letter in the abbreviation indicates the receptor protein at the amino terminus of the fusion protein. For example, ESU means a fusion protein having at least the ligand binding domain, hinge domain, and optionally functional DNA binding domain of *Drosophila* ecdysone receptor at the amino terminus, a linker containing 5 linker segments (of 12 amino acids each, plus the 5 amino acid linker bridge (i.e., a linker containing a total of 65 amino acids) and the comparable domains of the ultraspiracle protein. An initial "V" in the construct abbreviation, e.g., VESU or VE, indicates fusion of the VP16 τ activation domain to the N-terminus of the fusion protein, as described more completely hereafter.

Figure 1 is a schematic diagram of a nucleic acid construct encoding invention fusion proteins that contain EcR (darkly shaded) with a dimer partner, U (Usp) or R (RXR) (darkly shaded). "D" = DNA binding domain; "L" = ligand binding domain; curvilinear line = fusion bridge. "Individual" represents a nucleotide sequence that encodes the wild type C terminus of EcR (receptor) and the monomeric N-terminus of RXR (binding partner) before introduction of a nucleotide sequence encoding a fusion bridge. "Fused" represents the same segments with nucleotides inserted that encode a 5 amino acid fusion bridge containing the SfiI insertion site. "Tether" indicates a nucleotide sequence that encodes a 12 amino acid linker

to be inserted into the *Sfi*I site of the fusion bridge to produce fusion proteins with greater spacing between the two protein units (i.e., dimer partners) in the invention fusion protein.

Figures 2A-B illustrate the results of gel mobility shift assays of response element binding of the invention FD constructs having linkers containing either 0 or 5 linker segments as compared with that of monomeric receptor complexes (translated *in vitro*).

Figure 2A is a graph quantifying gel mobility shift as a result of response element binding to invention endodimer FDs in the presence of *murA*. Controls were treated either with vehicle (open bars) or with 1 μ M *murA* as ligand (black bars). Bars are labeled along the bottom with FDs named as described in the text. E represents an EcR only control; NON represents a non-transfected control. E+U and E+R are control lanes of monomeric *in vitro* translated proteins used for sizing of endodimer band shifts. Numbers at the top of each bar represent relative-fold increase in response element binding resulting from ligand treatment.

Figure 2B is a schematic representation of five F-domain deletion constructs containing EcR (darkly shaded) and RXR (lightly shaded) with no linker polypeptide (EOR). Incremental deletions are shown to *Nhe*I, *Pvu*II, *Nar*I, and *Bgl*II sites within the ecdysone receptor F domain. The top schematic represents EOR (1340 amino acids) containing the complete F-domain (bracketed); the second schematic represents a deletion (Δ 60 amino acids) to the *Nhe*I site; the third schematic represents a deletion (Δ 138 amino acids) to the *Pvu*II site; the fourth schematic represents a deletion (Δ 198 amino acids) to the *Nar*I site; and the fifth schematic represents a deletion (Δ 228 amino acids) to the *Bgl*II site.

Figure 3 is a graph showing relative luciferase expression induced by FD constructs with or without ligand as determined in transient transfection assays for FDs and for monomeric EcR with either *Usp* or *RXR* when treated with vehicle (open bars) or 1 μ M *murA*. Decimal numbers on the abscissa represent molar amount of FD relative to VE plasmid (1.0 is equimolar FD:VE). EOU and UOE without VE cotransfection are at the extreme right of the bar graph. See also Table 1.

Figures 4A-B are two graphs illustrating the results of transient transfection assays conducted using either VP16-fused monomeric receptors or invention fusion protein FDs with increasing linker lengths. Figure 4A is a graph showing a comparison of luciferase activity in relative light units (RLU) in transient transfection assays conducted with or without ligand, using either monomeric receptors having amino terminal fused VP16 activation domains or invention FDs containing EcR, RXR, and a linker with a variable number of linker segments. Cells were treated with vehicle (open bars), or 1 μ M *muristerone A* as ligand (black bars). Numbers at the top of the bars indicate the fold-increase relative to FD or monomeric receptor without addition of monomeric VRXR (VR) or monomeric VUsp (VU). E - EcR only; E4-luc - reporter plasmid only; and Figure 4B is a graph showing a comparison of luciferase activity as in Figure 4A herein, except that the FDs contain *Usp* in place of *RXR*.

Figure 5 is a series of three graphs showing repression of ligand-stimulated luciferase expression by monomeric receptors caused by competition with the invention ENU and UNE FDs when transiently co-transfected into 293 cells and treated either with vehicle (open bars), or 1 μ M muristerone A as ligand (black bars). Decimal numbers on the abscissa represent molar amount of FD relative to VE plasmid (1.0 is equimolar FD:VE). Figure 5A shows a comparison of the inhibitory effects of EOU and UOE on ligand-stimulated expression of luciferase by monomeric VE in combination with endogenous RXR. EOU and UOE without VE cotransfection are at the extreme right of the bar graph; Figure 5B shows the effects of monomeric EcR (without VP16 fusion) on ligand-stimulated expression of luciferase in the assay of Figure 5A by competition with EOU or UOE; and Figure 5C shows the effects of monomeric EcR on luciferase expression in the presence of ligand in the assay of Figure 5B, as compared with VE combined with monomeric exogenous Usp.

Figure 6 is a graph showing a comparison of results (in RLU) obtained in assays in which E5U and E5R compete with monomeric VRXR (VR) or monomeric VUsp (VU) in the presence of vehicle only (open bars) or murA as ligand (black bars). FDs and receptor combinations are labeled along the abscissa. Numbers above the bars represent the fold-increase relative to FD or receptor without addition of VR or VU. E4LUC at the extreme right is reporter plasmid alone as control.

Figures 7A-E are a series of six schematic diagrams representing possible conformations of receptor FDs described in the text. Shaded and white oval/rectangles represent receptors, small rectangles with interior arrows represent EcREs, and curvilinear lines represent linkers between protein units in the invention fusion proteins. Figure 7A represents a native dimer; Figure 7B represents a disorganized fusion protein; Figure 7C represents an endodimer orientation of a single invention FD; Figure 7D represents a tetramer of two invention FDs; Figure 7E represents a multimer of four invention FDs.

Figure 8 is a series of schematic representations of invention FDs containing *Bombyx* ecdysone receptor (BEcR) plus the entire F domain of the *Drosophila melanogaster* ecdysone receptor (amino acids 650 to 878) (DE), which segment is included for ease in making the construct (DEcR). The BEcR is at the amino terminus of the fusion protein with either RXR or Usp as the dimer partner at the carboxy terminus of the fusion protein. "D" - DNA binding domain; "L" - ligand binding domain; curvilinear line - fusion bridge. "H" - an N-terminal His tag for protein purification.

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, there are provided chimeric proteins comprising at least two functional protein units, wherein each functional protein unit comprises the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, and an optional linker interposed therebetween, wherein the at least two protein units form a functional entity. When the chimeric protein contains two functional protein units, the chimeric protein forms a functional dimer (FD), for example a heterodimer or a homodimer.

The invention chimeric proteins form functional entities (e.g. functional dimers) under a variety of conditions. Such conditions include, but are not limited to, those at or near physiological conditions (e.g., in saline at body temperature). Those of skill in the art will understand that formation of invention functional entities by dimerization or crystallization of a macromolecule can be influenced by manipulation of a variety of physical parameters, such as are disclosed in McPherson, *Eur. J. Biochem.*, **189**:1-23, 1990, which is incorporated herein by reference in its entirety. Due to the proximity of the protein units within the invention chimeric protein, dimerization tends to take place with intramolecular partners, rather than with other suitable monomeric dimer partners with which the protein units in the chimeric protein might otherwise interact.

As used herein, plural nouns and verbs are intended to signify the singular form as well as the plural form of the particular noun or verb, unless prefixed by an adjective indicating a specific number, such as "two feet" or "three ligands", and a singular noun or verb is intended to include the plural form, unless prefixed by a phrase clearly indicating that only the singular noun or verb is intended, as in the phrase "one and only one foot" or "only one ligand."

Each chimeric protein in the invention system is required to contain a dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily. As used herein, "dimerization domain" means a region of a member of the steroid/thyroid hormone nuclear receptor superfamily containing a sequence of amino acids that functions to cause dimerization of two members of the steroid/thyroid hormone nuclear receptor superfamily. Members of the steroid/thyroid hormone nuclear receptor superfamily are commonly characterized by the presence of five domains: N-terminal or activation domain (A/B), DNA binding domain (C), hinge domain (D), ligand binding domain (E), and C-terminal domain (F) (Evans, R. *Science* **240**:889-895, 1988). The dimerization domain is generally located within the region of the receptor molecule that is referred to as including the D, E and F domains, or is referred to as the "D-E-F" domain. Typically the dimerization domain includes the complete ligand binding domain (E) and may optionally include all or part of the hinge domain (D) and/or the C-terminal region (F) of a member of the steroid/thyroid nuclear receptor superfamily, or a functional equivalent thereof. In some cases the dimerization domain may include at least a portion of the DNA binding domain itself. Multiple domains of a given receptor can act in concert as well as independently. Therefore, as employed herein, the term "dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily" refers to that portion (or portions) of a member of the steroid/thyroid hormone nuclear receptor superfamily that is involved in the formation of a dimer.

As used herein, the term "fusion protein" means a genetically engineered molecule in which two or more polypeptide units are fused into a single polypeptide molecule by fusion of the open reading frames (ORFs) encoding the two or more separate protein units into a single ORF. The invention fusion proteins are capable of forming a "functional entity" in the optional presence of ligand. When the fusion proteins contain two protein units, a "functional dimer (FD)" is formed by dimerization.

As used herein, the term "functional dimer" or "functional entity" as applied to an invention chimeric protein means that the functional entity or dimer possesses at least some of the biological function of a dimer formed between two equivalent monomeric (i.e. undimerized) polypeptide units, or between two equivalent monomeric members of the

steroid/thyroid hormone nuclear receptor superfamily. The biological function of such dimers includes one or more of the following properties: DNA binding, ligand binding, transactivation, and dimerization properties related to transactivation of a promoter operatively associated with a response element responsive to the invention chimeric protein. For example, invention chimeric protein(s) can modulate transactivation of gene(s) whose expression is controlled by the presence of ligand (e.g. an invention FD wherein at least one member is a *Bombyx mori* ecdysone receptor can modulate the expression of a gene under the control of a *Bombyx* ecdysone response element).

Therefore, the term "functional protein units" as applied to the functional entity or dimer formed by an invention chimeric protein means that the at least two protein units in the functional entity or dimer possess a cooperative function. For example, in a functional dimer the two dimerization domains (e.g., the two protein units) fold and interact with each other in a manner appropriate to substantially preserve one or more of the above named biological functions in the functional dimer that are present when corresponding monomeric members of the dimer come together under physiological conditions to form a native dimer complex.

As used herein the term "endodimer" means a dimer formed in an orientation approximating that of a native dimer complex formed between equivalent monomeric polypeptides, i.e., an "internal" dimer. Figure 7A illustrates a native dimer complex and Figure 7C illustrates an invention endodimer.

As used herein the term "dimer partner" means any polypeptide that, under physiological conditions, forms a dimer with a member of the steroid/thyroid hormone nuclear receptor superfamily. Such dimer partners include, but are not limited to, monomeric member(s) of the steroid/thyroid hormone nuclear receptor superfamily, including those known in the art as a "silent partner," which are characterized by forming dimeric species with a member of the steroid/thyroid superfamily of receptors wherein the silent partner may not directly participate in binding ligand (i.e., only the co-partner in the fusion protein binds ligand). Exemplary dimer partner(s) include RXR, Usp, Nurr1, and the like.

The term "dimer partner" is meant to include members of the steroid/thyroid hormone nuclear receptor superfamily to which other wild type members preferentially bind to form heterodimeric species. For example, wild type members of the steroid/thyroid hormone nuclear receptor superfamily preferentially form heterodimers with a common partner, the retinoid X (or 9-cis retinoic acid) receptor (RXR, see, for example, Yu *et al.*, *Cell*, 67:1251-1266, 1991; Bugge *et al.*, *EMBO J.*, 11:1409-1418, 1992; Kliewer *et al.*, *Nature* 355:446-449, 1992; Leid *et al.*, *Cell* 68:377-395, 1992; Marks *et al.*, *EMBO J.* 11:1419-1435, 1992; Zhang *et al.*, *Nature* 355:441-446, 1992; Issemann *et al.*, *Biochimie*, 75:251-256, 1993). Additional dimer partners for members of the steroid/thyroid hormone nuclear receptor superfamily include *ultraspiracle* (Usp), farnesoid X receptor (FXR), and the like.

As used herein, the phrase "member(s) of the steroid/thyroid hormone nuclear receptor superfamily" (also known as "intracellular receptors" or "the nuclear receptor superfamily") refers to hormone binding proteins that operate as ligand-

dependent transcription factors, including identified members of the steroid/thyroid hormone nuclear receptor superfamily for which specific ligands have not yet been identified (referred to in the art as "orphan receptors").

Exemplary members of the steroid/thyroid hormone superfamily of receptors (including the various isoforms thereof) include steroid receptors such as glucocorticoid receptor (GR), mineralocorticoid receptor (MR), estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), vitamin D₃ receptor (VDR), and the like; plus retinoid receptors, such as the various isoforms of retinoic acid receptor (e.g., RAR α , RAR β or RAR γ), the various isoforms of retinoid X (or 9-*cis* retinoic acid) receptor (e.g., RXR α , RXR β , or RXR γ), various isoforms of peroxisome proliferator-activated receptors (e.g., PPAR α , PPAR β , PPAR γ) and the like (see, e.g., U.S. Patent Nos. 4,981,784; 5,171,671; and 5,071,773); thyroid hormone receptor (T₃R), such as TR α , TR β , and the like; steroid and xenobiotic receptor (SXR, see for example, Blumberg et al., *Genes Dev* (1998) 12(20):3195-205), RXR-interacting proteins (RIPs; see, e.g., Seol et al., *Mol Endocrinol* (1995) 9(1):72-85; Zavacki et al., *Proc Natl Acad Sci USA* (1997) 94(15):7909-14) including farnesoid X receptor (FXR; see for example, Forman et al., *Cell* (1995) 81(5):687-93; Hanley et al., *J Clin Invest* (1997) 100(3):705-12, O'Brien et al., *Carcinogenesis* (1996) 17(2):185-90), pregnenolone X receptor (PXR; see for example, Schuetz et al., *Mol Pharmacol* (1998) 54(6):1113-7), liver X receptor (LXR, see, e.g., Peet et al., *Curr Opin Genet Dev* (1998) 8(5):571-5), BXR (Blumberg et al., *Genes Dev* (1998) 12(9):1269-77), insect derived receptors such as the ecdysone receptor (EcR), the ultraspiracle receptor (see, for example, Oro et al., in *Nature* 347:298-301 (1990)), and the like; as well as other gene products which, by their structure and properties, are considered to be members of the superfamily, as defined hereinabove, including the various isoforms thereof (see, e.g., Laudet, V., *J Mol Endocrinol* (1997) 19(3):207-26).

Examples of orphan receptors contemplated for use herein include HNF4 (see, for example, Sladek et al., *Genes & Development* 4:2353-2365 (1990)), the COUP family of receptors (see, for example, Miyajima et al., in *Nucleic Acids Research* 16:11057-11074 (1988), and Wang et al., *Nature* 340:163-166 (1989)), COUP-like receptors and COUP homologs, such as those described by Mlodzik et al., *Cell* 60:211-224 (1990) and Ladas et al., *Science* 251:561-565 (1991), orphan receptor (OR1; see, e.g., Feltkamp et al., *J Biol Chem* (1999) 274(15):10421-9), the insect derived knirps and knirps-related receptors, short heterodimer partner (SHP; see, e.g., Seol et al., *Mol Cell Biol* (1997) 17(12):7126-31), hepatocyte nuclear receptor 4 (HNF4), constitutive androstane receptor (CAR; see, e.g., Forman et al., *Nature* (1998) 395(6702):612-5), and the like.

Each protein unit in the invention chimeric protein is required to contain at least a dimerization domain, optionally, the entire ligand binding domain, an optional hinge domain, and an optionally functional DNA binding domain of a member of the steroid/thyroid nuclear receptor superfamily, or a functional equivalent thereof. For use in the invention methods for modulating the transcription of exogenous or endogenous nucleic acids in a host, the ligand binding domains are either endogenous or non-endogenous to a host, with the latter including ligand binding domains that are modified to be non-responsive to ligands endogenous or native to the host. In embodiments wherein the ligand binding domain is derived from non-mammalian member(s) of the steroid/thyroid hormone nuclear receptor superfamily, which members are not normally present in the cells of a host, the

ligand binding domains are preferably derived from the carboxy-terminal portion of non-mammalian members. Exemplary members that are not normally present in mammalian cells include insect, avian, amphibian, reptilian, fish, plant, bacteria, viral and fungal (including yeast) members of the steroid/thyroid hormone nuclear receptor superfamily, and the like.

Exemplary ligand binding domains derived from insect receptors include those derived from lepidopteran species such as
5 *Drosophila melanogaster* (M.R. Koelle, 1995), *Bombyx mori* (Swevers *et al.*, *Insect Biochem. Molec. Biol.*, 25(7):857-866, 1995),
Choristoneura fumiferana (Palli *et al.*, *Insect Biochem. Molec. Biol.*, 26(5):485-499, 1996), *Manduca sexta* (Fujiwara *et al.*, *Insect*
Biochem. Molec. Biol., 25(7):845-856, 1995), *Aedes aegypti* (Cho *et al.*, *Insect Biochem Molec. Biol.*, 25:19-27, 1995),
Chorinomos tentans (Imhof *et al.*, *Insect Biochem. Molec. Biol.*, 25:115-124, 1993), and the like.

When the functional protein units included in the invention chimeric protein lack a substantial portion of the C-terminal
10 "F" domain in the dimerization domain of a native member of the steroid/thyroid hormone nuclear receptor superfamily, a
functional protein unit that is less than about 700 amino acids in length is provided.

Ligand binding domains can be functionally located in either orientation and at various positions within the protein unit.
For example, the ligand binding domain can be positioned at either the amino or carboxy terminus of the protein unit in the
15 invention chimeric protein, or therebetween. In a preferred embodiment of the present invention, the ligand binding domain is
positioned at the carboxy terminus of the protein unit (see Figure 1).

The optional hinge region, when present, can also be functionally located in either orientation and at various positions
within the protein unit. For example, the hinge region can be positioned at either the amino or carboxy terminus of the protein
unit, or therebetween. Preferably, the hinge region is positioned internally between the ligand binding and DNA binding domains
20 of one or more of the members in the chimeric protein. The hinge region bounded by the ligand binding domain and DNA binding
domain of the native *Bombyx mori* receptor (BEcR), specifically, about 27 amino acid residues (i.e. amino acid residues 283-309,
in the hinge region of BEcR) are sufficient to confer high affinity for complex formation with an endogenous dimer partner (see
U.S. Patent Application Serial No. 08/891,298, filed July 10, 1997, copending herewith).

Each protein unit in the invention chimeric protein also optionally contains a DNA binding domain. DNA-binding domains
25 contemplated for use in the preparation of invention chimeric proteins are well known in the art and are typically obtained from
DNA-binding proteins (e.g., transcription factors). The term "DNA-binding domain" is understood in the art to refer to an amino
acid sequence that is able to bind to DNA. As used herein, the term "DNA-binding domain" encompasses a minimal peptide
sequence of a DNA-binding protein up to the entire length of a DNA-binding protein, so long as the DNA-binding domain functions
to associate with a particular regulatory element.

30 DNA-binding domains are known to function heterologously in combination with other functional domains by
maintaining the ability to bind the natural DNA recognition sequence (see, e.g., Brent and Ptashne, *Cell*, 43:729-736, 1985). For

example, with respect to steroid/thyroid hormone nuclear receptors, DNA-binding domains are interchangeable, thereby providing numerous chimeric receptor proteins (see, e.g., U.S. Patent 4,981,784; and R. Evans, *Science*, **240**:889-895, 1988). Similar to the ligand binding domain, the DNA-binding domain can be positioned at either the carboxy terminus or the amino terminus of a protein unit in the invention chimeric protein, or the DNA-binding domain can be positioned between the ligand binding domain and the activation domain. In preferred embodiments of the present invention, the DNA-binding domain is positioned internally between the ligand binding domain and the activation domain.

"DNA-binding protein(s)" contemplated for use herein belong to the well-known class of proteins that are able to directly bind DNA and facilitate initiation or repression of transcription. Exemplary DNA-binding proteins contemplated for use herein include transcription control proteins (e.g., transcription factors and the like; see, for example, Conaway and Conaway, *Transcription Mechanisms and Regulation*, Raven Press Series on Molecular and Cellular Biology, Vol. 3, Raven Press, Ltd., New York, NY, 1994).

Transcription factors contemplated for use herein as a source of such DNA binding domains include, e.g., homeobox proteins, zinc finger proteins, hormone receptors, helix-turn-helix proteins, helix-loop-helix proteins, basic-Zip proteins (bZip), β -ribbon factors, and the like. See, for example, S. Harrison, "A Structural Taxonomy of DNA-binding Domains," *Nature*, **353**:715-719. Homeobox DNA-binding proteins suitable for use herein include, for example, HOX, STF-1 (Leonard *et al.*, *Mol. Endo.*, **7**:1275-1283, 1993), Antp, Mat α -2, INV, and the like. See, also, Scott *et al.* *Biochem. Biophys. Acta*, **989**:25-48, 1989. It has been found that a fragment of 76 amino acids (corresponding to amino acids 140-215 described in Leonard *et al.*, 1993) containing the STF-1 homeodomain binds DNA as tightly as wild-type STF-1. Suitable zinc finger DNA-binding proteins for use herein include Zif268, GLI, XFin, and the like. See also, Klug and Rhodes, *Trends Biochem. Sci.*, **12**:464, 1987; Jacobs and Michaels, *New Biol.*, **2**:583, 1990; and Jacobs, *EMBO J.*, **11**:4507-4517, 1992.

An additional DNA binding domain contemplated for use in the practice of the present invention is the GAL4 DNA binding domain. The DNA binding domain of the yeast GAL4 protein comprises at least the first 74 amino terminal amino acids thereof (see, for example, Keegan *et al.*, *Science* **231**:699-704, 1986). Preferably, the first 90 or more amino terminal amino acids of the GAL4 protein will be used, for example, the 147 amino terminal amino acid residues of yeast GAL4.

The DNA-binding domain(s) used in the invention chimeric proteins can be obtained from a member of the steroid/thyroid hormone nuclear receptor superfamily, or are substantially the same as those obtained from a member of the superfamily. The DNA-binding domains of all members of the steroid/thyroid hormone nuclear receptor superfamily are related. Such domains consist of 66-68 amino acid residues, and possess about 20 invariant amino acid residues, including nine cysteines. Members of the superfamily are characterized as proteins which contain these 20 invariant amino acid residues. The highly conserved amino acids of the DNA-binding domain of members of the superfamily are as follows:

Cys - X - X - Cys - X - X - Asp* - X - Ala* - X - Gly* - X - Tyr* - X - X - X - Cys - X - X -
Cys - Lys* - X - Phe - Phe - X - Arg* - X - X - X - X - X - (X - X -) Cys - X - X - X - X - X - (X -

X - X -) Cys - X - X - X - Lys - X - X - Arg - X - X - Cys - X - X - Cys - Arg* - X - X -
 Lys* - Cys - X - X - X - Gly* - Met (SEQ ID NO:1);

wherein X designates non-conserved amino acids within the DNA-binding domain; an asterisk denotes the amino acid residues which are almost universally conserved, but for which variations have been found in some identified hormone receptors; and the residues enclosed in parenthesis are optional residues (thus, the DNA-binding domain is a minimum of 66 amino acids in length, but can contain several additional residues).

Invention chimeric proteins are optionally modified by the introduction of an activation domain subunit. Activation domains contemplated for use in the practice of the present invention are well known in the art and can readily be identified by those of skill in the art. Such activation domains are typically derived from transcription factors and comprise a contiguous sequence that functions to activate gene expression when associated with a suitable DNA-binding domain and a suitable ligand binding domain. An activation domain can be positioned at any convenient site within the invention chimeric protein, e. g., at the carboxy terminus, the amino terminus, or between the ligand binding domain and the DNA binding domain within one or both protein units of the chimeric protein. In presently preferred embodiments of the invention, the activation domain is positioned at the amino terminus of the invention chimeric protein.

Suitable activation domains can be obtained from a variety of sources, e.g., from the N-terminal region of members of the steroid/thyroid hormone nuclear receptor superfamily, from transcription factor activation domains, such as, for example, VP16, GAL4, NF-kB or BP64 activation domains, and the like. The activation domain presently preferred for use in the practice of the present invention is obtained from the C-terminal region of the VP16 protein, and is known as VP16c.

In a presently preferred embodiment of the present invention, chimeric proteins contain one or more ecdysone receptors (EcR) as the steroid/thyroid hormone nuclear receptor, for example, a *Drosophila* EcR (DEcR) or a *Bombyx* EcR (BEcR). The chimeric protein further comprises either RXR or *ultraspiracle* protein (Usp) as an additional functional protein unit. The preferred order within the chimeric protein is for the EcR to be located at the amino terminus of the chimeric protein. However, when the invention chimeric protein further comprises an activation domain, the activation domain is preferably located at the amino terminus of the chimeric protein.

The EcR, an insect receptor, differs in two respects from other known steroid/thyroid hormone nuclear receptor superfamily. First, EcR has very different documented relationships with two similar dimer partners: its natural partner, Usp, and the mammalian homolog, RXR. EcR also differs from other members of the steroid/thyroid hormone nuclear receptor superfamily in that its apparent affinity to these heterodimer partners varies depending on the presence of ligand.

To facilitate dimerization of the dimerization domains in the invention chimeric proteins, the at least two protein units of the chimeric protein preferably have the ligand binding domain, hinge domain, and DNA binding domain in the same order within each protein unit. If the chimeric protein additionally contains an activation domain, the activation domain is

preferably located at the amino terminus of the chimeric protein, ahead of the first unit thereof, as illustrated in Examples 1 and 4 herein.

Invention chimeric protein(s) optionally further contain a linker interposed between one or more of the protein units. The protein units can be independently oriented amino terminus to carboxy terminus within the chimeric protein, or *visa versa*. For example, the linker can be placed between the carboxy terminus of the first protein unit and the amino terminus of the second protein unit. Any type of linker known in the art can be used for linking the protein units in invention chimeric proteins so long as the linker is flexible and does not interfere with dimerization between protein units in the invention chimeric proteins.

In one embodiment according to the present invention, the linker is a heterobifunctional cleavable cross-linker, such as N-succinimidyl (4-iodoacetyl)-aminobenzoate; sulfosuccinimidyl(4-iodoacetyl)-aminobenzoate; 4-succinimidyl-oxycarbonyl- α -(2-pyridyldithio) toluene; sulfosuccinimidyl-6-[α -methyl- α -(pyridyldithio)-toluamido] hexanoate; N-succinimidyl-3-(2-pyridyldithio)-propionate; succinimidyl-6-[3-(2-pyridyldithio)-propionamido] hexanoate; sulfosuccinimidyl-6-[3-(2-pyridyldithio)-propionamido] hexanoate; 3-(2-pyridyldithio)-propionyl hydrazide, Ellman's reagent, dichlorotriazinic acid, S-(2-thiopyridyl)-L-cysteine, and the like. Further bifunctional linking compounds are disclosed in U.S. Patent Nos. 5,349,066, 5,618,528, 4,569,789, 4,952,394, and 5,137,877, each of which is incorporated herein by reference in its entirety. These chemical linkers can be attached to purified proteins using numerous protocols known in the art, such as those described in Pierce Chemicals "Solutions, Cross-linking of Proteins: Basic Concepts and Strategies," Seminar #12, Rockford, IL.

In another embodiment according to the present invention, the linker can be a peptide having from about 2 to about 60 amino acid residues, for example from about 5 to about 40, or from about 10 to about 30 amino acid residues, such as known in single-chain antibody research. Examples of such known linker moieties include GGGGS (SEQ ID NO:2), (GGGGGS)_n (SEQ. ID NO:3), GKSSGSGSESKS (SEQ ID NO:4), GSTSGSGKSSEGKG (SEQ. ID NO:5), GSTSGSGKSSEGSGSTKG (SEQ ID NO:6), GSTSGSGKSSEGKG (SEQ ID NO:7), GSTSGSGKPGSGEGSTKG (SEQ ID NO:8), EGKSSGSGSESKF (SEQ ID NO:9), SRSSG (SEQ. ID NO:10), SGSSC (SEQ ID NO:11), and the like. A *Diphtheria* toxin trypsin sensitive linker having the sequence AMGRSGGGCAGNRVGSSLSCGGLNLQAM (SEQ ID NO:12) is also useful. Alternatively, the peptide linker moiety can be VM or AM, or have the structure described by the formula: AM(G₂₋₁₂,S)_XAM wherein X is an integer from 1 to 11 (SEQ ID NO:13). Additional linking moieties are described, for example, in Huston *et al.*, *PNAS* 85:5879-5883, 1988; Whitlow, M., *et al.*, *Protein Engineering* 6:989-995, 1993; Newton *et al.*, *Biochemistry* 35:545-553, 1996; A. J. Cumber *et al.*, *Bioconj. Chem.* 3:397-401, 1992; Ladurner *et al.*, *J. Mol. Biol.* 273:330-337, 1997; and U.S. Patent. No. 4,894,443, the latter of which is incorporated herein by reference in its entirety.

Generally, however, the linker contains from about 5 to about 245 amino acids, although there is no theoretical upper limit on the number of amino acids that could be used in the linker. Preferably, the linker contains from about 53 to about 125 amino acids. The amino acids in the linker protein are preferably selected to provide flexibility to the linker.

Preferably, a multiplicity of flexibility enhancing amino acids, such as proline, glycine, alanine and serine, are incorporated into the linker to enhance its flexibility.

Assuming a span of approximately 3.35 angstroms per amino acid within the flexible peptide bridge encoded by a 36-base pair *Sfi*I compatible oligonucleotide, the predicted minimum and maximum distance for the lengths of the linker having from 0 to 20 linker segments ranges from about 16.75 angstroms (the 5 amino acid bridge) to 804 angstroms (20-linker segments + the 5 amino acid bridge). Thus, the length of the linker can readily be selected to enhance dimerization between any two particular members acting as dimer partners by including as many linker segments as is preferred to enhance the biological functions of the functional dimer, as discussed herein.

In a presently preferred embodiment, the nucleotide encoding the polypeptide linker contains a restriction endonuclease recognition site which produces an overhang composed of non-palindromic center bases to allow for insertion of compatible inserts in a uniform orientation and in continually in-frame blocks along the length of the polypeptide linker. This type of linker allows incremental expansion of the linker peptide to produce chimeric proteins containing linkers with a range of distances between the protein units. The nucleotide encoding the linker preferably contains a rare 8-base-pair *Sfi*I recognition site that is useful in making constructs with linkers of variable length. In addition, the nucleotides composing the recognition site:

-GGCCNNNNNGGCC- (SEQ ID NO:14)

are guanidines and cytosines, which can be oriented in frame to encode glycine and proline residues in accordance with the criteria of producing a "flexible" protein linker for junction of the two units of the chimeric protein. Any bases can be used as the "N" nucleotides contained within the recognition site, allowing further flexibility in the design of the linker.

A presently preferred linker amino acid sequence is GPGGGSGGGSGT (SEQ ID NO:15), which provides a high degree of predicted flexibility while minimizing repetitive sequence within the encoding oligonucleotide.

In accordance with another embodiment of the present invention, there are provided nucleotides encoding invention chimeric protein(s) and cells containing such nucleotides. Cells containing invention polynucleotides can be either mammalian or non-mammalian, for example, plant or fungi cells, and the like.

In accordance with another embodiment of the present invention, there are provided methods for modulating the expression of exogenous gene(s) in a subject organism containing:

- 1) a functional entity according to the invention and
- 2) a DNA construct encoding and expressing the exogenous gene(s) under the control of a response element responsive to the functional dimer.

Invention methods for modulating exogenous gene expression in such a subject organism comprise administering to the subject organism an effective amount of at least one ligand for the functional dimer.

Ligand is selected to activate at least one functional unit of the functional entity. When the functional entity is a functional dimer, the ligand is usually selected to activate the dominant member of the functional dimer. For example, if one of the two members in the functional dimer is a silent dimer partner, the ligand is selected to activate the member in the functional dimer that does not act as a silent dimer partner.

In a presently preferred embodiment of the present invention, one of the members in the functional entity is from an insect species, and the preferred ligand is an insect hormone. For example, preferred insect receptors are the *Drosophila* ecdysone receptor or the *Bombyx* ecdysone receptor, and the preferred dimer partner with these insect receptors in the invention chimeric protein is either the *ultraspiracle* protein or a retinoid X receptor. These functional entities complex with the ecdysone response element, generally in the presence of ligand for the functional dimer formed by the invention chimeric protein, but in some instances the presence of ligand is not required to form a functional entity/response element complex, as explained more fully hereinbelow.

As employed herein, the terms "modulate" and "modulating" refer to the ability of a given functional entity to activate/deactivate and/or up-regulate/down-regulate transcription of exogenous nucleic acids, relative to the transactivation activity in the absence of the functional entity.

The actual effect of an invention functional entity on the transcription of exogenous or endogenous nucleic acids will vary depending on the particular combination of dimerization domains and/or members of the steroid/thyroid hormone nuclear receptor superfamily in the chimeric protein, on the presence or absence of specific ligand for the ligand binding domain(s) employed in the chimeric protein, and on the regulatory element (e.g., response element) with which the selected chimeric protein interacts. It is specifically contemplated within the scope of the present invention that modulation includes repression of expression of one or more genes. Such repression can be either ligand-dependent repression or repression that occurs independently of the presence of a ligand. Thus, there are four types of modulation contemplated within the scope of the invention: ligand-dependent induced modulation, ligand-dependent repressed modulation, ligand-independent induced modulation, and ligand independent repressed modulation. The ligand can be either exogenous or endogenous to the subject treated for modulation of expression of an exogenous gene.

More particularly, the type of modulation that results from the practice of the invention method (i.e., whether activation or repression of expression of the exogenous gene) depends upon the combination of dimerization domains and/or members of the steroid/thyroid hormone nuclear receptor superfamily contained within a functional entity formed by the invention chimeric protein. For example, it has been determined that activation of expression of the exogenous gene(s) according to the invention modulation method can be achieved if the dimer partners in an invention FD used in the invention method of modulation are an ecdysone receptor and a retinoid X receptor, e.g. EOR or ESR. Ligands suitable for activating expression of the exogenous gene(s)

when such functional dimers are employed in the invention methods include muristerone A, 20-hydroxyecdysone, phytoecdysteroid(s), and the like.

On the other hand, it has been determined that expression of an exogenous gene(s) can be repressed independently of (i.e., with or without) the presence of ligand if an invention FD comprising an ecdysone receptor (e.g., either a *Drosophila* ecdysone receptor or a *Bombyx* ecdysone receptor) and an *ultraspiracle* protein as dimer partner is used in the invention method, e.g., ESU, and the like. Ligands suitable for activating expression of the exogenous gene(s) when such functional dimers are employed in the invention methods are 20-hydroxyecdysone, muristerone A, phytoecdysteroid(s), and the like. In addition, expression of exogenous gene(s) can be repressed independently of (i.e., with or without) the presence of ligand if an invention FD comprising a *Bombyx* ecdysone receptor and an RXR as dimer partner is used in the invention method. As shown in Example 6 herein, an N-terminal His tag on the chimeric protein to aid in protein purification does not effect binding of the chimeric protein to a suitable response element so as to repress expression of the exogenous gene according to invention methods for modulating expression of exogenous gene(s).

Accordingly, in another embodiment of the present invention, there are provided methods for modulating (i.e., either activating or repressing) the expression of one or more genes in a subject organism independently of the presence of ligand for the invention chimeric protein. If the subject organism contains an invention chimeric protein, the invention method comprises introducing to the subject an exogenous response element(s) with which the chimeric protein interacts and which controls expression of the one or more genes, thereby modulating expression of the gene(s) independent of the presence of ligand for the chimeric protein. On the other hand, if the subject organism contains an exogenous response element(s) controlling expression of the one or more genes, the invention method comprises introducing to the subject an invention chimeric protein with which the response element interacts, thereby modulating expression of the gene(s) independent of the presence of ligand for the chimeric protein.

In accordance with another embodiment of the present invention, there are provided methods for modulating (i.e., either activating or repressing) the expression of one or more exogenous genes independent of ligand for the chimeric protein. If the subject contains a chimeric protein according to the invention, the invention method comprises introducing to the subject an effective amount of a response element, wherein the response element is responsive to the chimeric protein and wherein the modulation is independent of ligand for the chimeric protein. The modulation can be ligand independent activation or ligand independent repression.

In accordance with another embodiment of the present invention, there are provided methods for modulating (i.e., either activating or repressing) the expression of one or more exogenous genes in a cell containing:

- 1) an invention chimeric protein and
- 2) a DNA construct comprising the exogenous gene under the control of a response element with which the chimeric protein interacts, wherein said response element controls expression of the exogenous gene,

said method comprising administering to the cell an effective amount of an exogenous ligand for at least one functional unit of the chimeric protein.

In accordance with another embodiment of the present invention, there are provided methods for modulating the expression of one or more genes in a subject organism containing an endogenous response element controlling expression of one or more genes. The invention method in this situation comprises introducing to the subject an invention chimeric protein, wherein the chimeric protein interacts with the response element, thereby modulating expression of the gene(s) dependent on the presence of endogenous ligand therefor. The chimeric protein is encoded by an inducible DNA construct and the modulating comprises inducing expression of the gene(s).

In another embodiment according to the present invention, there are provided methods for modulating the expression of one or more genes in a subject organism containing an endogenous response element controlling expression of one or more genes and an endogenous ligand. The invention method comprises introducing to the subject an invention chimeric protein that interacts with the endogenous ligand and wherein the chimeric protein interacts with the response element, thereby modulating expression of the gene(s) dependent on the presence of the endogenous ligand. If the invention chimeric protein is encoded by an inducible DNA construct, the modulating further comprises inducing expression of the chimeric protein. This embodiment of the invention is especially useful for controlling expression of an exogenous gene that is under the control of an endogenous response element wherein the ligand for the invention functional dimer is also endogenous.

Response elements contemplated for use in the practice of the present invention (relating to modulation of the expression of exogenous genes in a subject) include native, as well as modified response elements. For example, since invention functional dimers can function as either homodimers or as heterodimers (with a silent partner therefor), any response element that is responsive to an invention functional dimer, in the form of a homodimer or heterodimer, is contemplated for use in the invention methods described herein. As is readily recognized by those of skill in the art, invention functional dimers (whether in the form of a homodimer or a heterodimer) can bind to a response element having an inverted repeat motif (i.e., two or more half sites in mirror image orientation with respect to one another), to a response element having a direct repeat motif, and the like.

Response elements useful in conjunction with invention functional entities are those well known in the art. As readily recognized by those of skill in the art, the response element employed will vary as a function of the protein units incorporated into the functional entity. Thus, for example, retinoic acid receptor response elements are composed of at least one direct repeat of two or more defined half sites separated by a spacer of five nucleotides. The spacer nucleotides can independently be selected from any one of A, C, G or T. Each half site of response elements contemplated for use in the practice of the invention comprises the sequence:

·RGBNNM·,

wherein

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence -AGGTCA-. Response elements employed in the practice of the present invention can optionally be preceded by N_x, wherein x falls in the range of 0 up to 5.

For example, thyroid hormone receptor response elements can be composed of the same half site repeats, with a spacer of four nucleotides. Alternatively, palindromic constructs as have been described in the art are also functional as TR response elements.

Exemplary GAL4 response elements are those containing the palindromic 17-mer:

5'-CGGAGGACTGTCTCCG-3' (SEQ ID NO:16),

such as, for example, 17MX, as described by Webster et al., in *Cell* 52:169-178 (1988), as well as derivatives thereof.

Additional examples of suitable response elements include those described by Hollenberg and Evans in *Cell* 55:899-906 (1988); or Webster et al. in *Cell* 54:199-207 (1988).

Ecdysone response element sequences are preferred for use herein with functional dimers containing an ecdysone receptor function in a position- and orientation-independent fashion. The native ecdysone response element has been previously described, see, e.g., Yao et al., *Cell*, 71:63-72, 1992.

In the invention methods the operative response element is functionally linked to an operative exogenous gene(s) whose expression it is desirable to control. The word "operative" means that the respective DNA sequences (represented by the terms "response element" and "exogenous or endogenous gene") are operational, i.e., work for their intended purposes; the word "functionally" means that after the two segments are linked, upon appropriate activation by a functional dimer/ligand complex, the exogenous gene(s) will be expressed as the result of the fact that the "response element" was "turned on" or otherwise activated.

Certain nucleic acid constructs contemplated for use in one aspect of the present invention include promoters and regulatory elements operatively associated with exogenous nucleic acids. In one embodiment of the present invention, the invention functional dimer, in the presence of a ligand therefor, binds the regulatory element and activates transcription of one or more exogenous nucleic acids. For example, an invention functional dimer containing the protein units RXR and EcR will transactivate an ecdysone response element-containing promoter in the presence of the hormone ecdysone, or the synthetic analog, muristerone A.

Regulatory elements contemplated for use in the practice of the present invention include elements responsive to the invention receptor peptide. In a preferred embodiment of the present invention, such elements are exogenous regulatory elements not normally present in the cells of the host. One class of exogenous regulatory elements contemplated for use herein includes hormone response elements that modulate transcription of exogenous nucleic acid when bound to the DNA binding domain of an invention receptor peptide.

Regulatory elements employed in the practice of the present invention are operably linked to a suitable promoter for transcription of exogenous nucleic acid(s) product(s). As used herein, the term "promoter" refers to a specific nucleotide sequence recognized by RNA polymerase, the enzyme that initiates RNA synthesis. The promoter sequence is the site at which transcription can be specifically initiated under proper conditions. When exogenous nucleic acid(s), operatively linked to a suitable promoter, is(are) introduced into the cells of a suitable host, expression of the exogenous nucleic acid(s) is(are) controlled in many, but not all cases, by the presence of ligands, which are not normally present in the host cells.

Promoters contemplated for control of expression of exogenous nucleic acids employed in the practice of the present invention include inducible (e.g., minimal CMV promoter, minimal TK promoter, modified MMLV LTR), constitutive (e.g., chicken β -actin promoter, MMLV LTR (non-modified), DHFR), and/or tissue specific promoters.

Inducible promoters contemplated for use in the practice of the present invention comprise transcription regulatory regions that function maximally to promote transcription of mRNA under inducing conditions. Examples of suitable inducible promoters include DNA sequences corresponding to: the *E. coli* lac operator responsive to IPTG (see Nakamura *et al.*, *Cell*, 18:1109-1117, 1979); the metallothionein promoter metal-regulatory-elements responsive to heavy-metal (e.g., zinc) induction (see Evans *et al.*, U.S. Patent No. 4,870,009), the phage T7lac promoter responsive to IPTG (see Studier *et al.*, *Meth. Enzymol.*, 185: 60-89, 1990; and U.S. Patent No. 4,952,496), the heat-shock promoter; the TK minimal promoter; the CMV minimal promoter; a synthetic promoter; and the like.

Exemplary constitutive promoters contemplated for use in the practice of the present invention include the CMV promoter, the SV40 promoter, the DHFR promoter, the mouse mammary tumor virus (MMTV) steroid-inducible promoter, Moloney murine leukemia virus (MMLV) promoter, elongation factor 1a (EF1a) promoter, albumin promoter, APO A1 promoter, cyclic AMP dependent kinase II (CaMKII) promoter, keratin promoter, CD3 promoter, immunoglobulin light or heavy chain promoters, neurofilament promoter, neuron specific enolase promoter, L7 promoter, CD2 promoter, myosin light chain kinase promoter, HDX gene promoter, thymidine kinase (TK) promoter, RNA Pol II promoter, MYOD promoter, MYF5 promoter, phosphoglycerokinase (PGK) promoter, Stf1 promoter, Low Density Lipoprotein (LDL) promoter, chicken b-actin promoter (used in conjunction with ecdysone response element), and the like.

As readily understood by those of skill in the art, the term "tissue specific" refers to the substantially exclusive initiation of transcription in the tissue from which a particular promoter that drives expression of a given gene is derived (e.g., expressed only in T-cells, endothelial cells, smooth muscle cells, and the like). Exemplary tissue specific promoters contemplated for use in

the practice of the present invention include the GH promoter, the NSE promoter, the GFAP promoter, neurotransmitter promoters (e.g., tyrosine hydroxylase, TH, choline acetyltransferase, ChAT, and the like), promoters for neurotropic factors (e.g., a nerve growth factor promoter, NT-3, BDNF promoters, and the like), and so on.

5 As used herein, when referring to nucleic acids, the phrase "exogenous to said mammalian host" or simply "exogenous" refers to nucleic acids not naturally found at levels sufficient to provide a function in the particular cell where transcription is desired. For example, exogenous nucleic acids can be either natural or synthetic nucleic acids, which are introduced into the host in the form of DNA or RNA. The nucleic acids of interest can be introduced into target cells (for *in vitro* applications), or the nucleic acids of interest can be introduced directly or indirectly into a host, for example, by the transfer of transformed cells into a host.

10 In contrast to exogenous nucleic acids, the phrase "endogenous nucleic acids" or "endogenous genes" refers to nucleic acids naturally found at levels sufficient to provide a function in the particular cell where transcription is desired.

Exogenous nucleic acids contemplated for use in the practice of the present invention include wild type and/or therapeutic nucleic acids. "Wild type" genes are those that are native to cells of a particular type. Exemplary wild type nucleic acids are genes which encode products the substantial absence of which leads to the occurrence of a non-normal state in a host; 15 or a substantial excess of which leads to the occurrence of a non-normal state in a host.

Such genes may not be expressed in biologically significant levels or may be undesirably overexpressed. Thus, for example, while a synthetic or natural gene coding for human insulin would be exogenous genetic material to a yeast cell (since yeast cells do not naturally contain insulin genes), a human insulin gene inserted into a human skin fibroblast cell would be a wild type gene with respect to the fibroblast since human skin fibroblasts contain genetic material encoding human insulin, although 20 human skin fibroblasts do not express human insulin in biologically significant levels.

Therapeutic nucleic acids contemplated for use in the practice of the present invention include those which encode products which are toxic to the cells in which they are expressed; or encode products which impart a beneficial property to a host; or those which transcribe nucleic acids which modulate transcription and/or translation of endogenous genes.

As employed herein, the phrase "therapeutic nucleic acids" refers to nucleic acids that impart a beneficial function to 25 the host in which such nucleic acids are transcribed. Therapeutic nucleic acids are those that are not naturally found in host cells. For example, synthetic or natural nucleic acids coding for wild type human insulin would be therapeutic when inserted into a skin fibroblast cell so as to be expressed in a human host, where the human host is not otherwise capable of expressing functionally active human insulin in biologically significant levels. Further examples of therapeutic nucleic acids include nucleic acids that transcribe antisense constructs used to suppress the expression of endogenous genes. Such antisense transcripts bind 30 endogenous nucleic acid (mRNA or DNA) and effectively cancel out the expression of the gene. In accordance with the methods described herein, therapeutic nucleic acids are expressed at a level that provides a therapeutically effective amount of the corresponding therapeutic protein.

Exogenous nucleic acids useful in the practice of the present invention include genes that encode biologically active proteins of interest, such as, e.g., secretory proteins that can be released from said cell; enzymes that can metabolize a toxic substance to produce a non-toxic substance, or that metabolize an inactive substance to produce a useful substance; regulatory proteins; cell surface receptors; and the like. Useful genes include genes that encode blood clotting factors, such as human factors VIII and IX; genes that encode hormones, such as insulin, parathyroid hormone, luteinizing hormone releasing factor (LHRH), alpha and beta seminal inhibins, and human growth hormone; genes that encode proteins, such as enzymes, the absence of which leads to the occurrence of an abnormal state; genes encoding cytokines or lymphokines such as interferons, granulocytic macrophage colony stimulating factor (GM-CSF), colony stimulating factor-1 (CSF-1), tumor necrosis factor (TNF), and erythropoietin (EPO); genes encoding inhibitor substances such as alpha₁-antitrypsin; genes encoding substances that function as drugs, e.g., genes encoding the diphtheria and cholera toxins; and the like.

Additional nucleic acids contemplated for use in accordance with the present invention include genes that encode proteins present in dopaminergic neurons (useful, for example, for the treatment of Parkinson's disease), cholinergic neurons (useful, for example, for the treatment of Alzheimer's disease), hippocampal pyramidal neurons (also useful for the treatment of Alzheimer's disease), norepinephrine neurons (useful, for example, for the treatment of epilepsy), spinal neurons (useful, for example, for the treatment of spinal injury), glutamatergic neurons (useful, for example, for the treatment of schizophrenia), cortical neurons (useful, for example, for the treatment of stroke and brain injury), motor and sensory neurons (useful, for example, for the treatment of amyotrophic lateral sclerosis), and the like.

Typically, nucleic acid sequence information for proteins encoded by exogenous nucleic acid(s) contemplated for use employed herein can be located in one of many public access databases, e.g., GENBANK, EMBL, Swiss-Prot, and PIR, or in related journal publications. Thus, those of skill in the art have access to sequence information for virtually all known genes. Those of skill in the art can obtain the corresponding nucleic acid molecule directly from a public depository or from the institution that published the sequence. Optionally, once the nucleic acid sequence encoding a desired protein has been ascertained, the skilled artisan can employ routine methods, e.g., polymerase chain reaction (PCR) amplification, to isolate the desired nucleic acid molecule from the appropriate nucleic acid library. Thus, all known nucleic acids encoding proteins of interest are available for use in the methods and products described herein.

Additional components that can optionally be incorporated into the invention constructs include selectable markers and genes encoding proteins required for retroviral packaging, e.g., the *pol* gene, the *gag* gene, the *env* gene, and the like.

Selectable markers contemplated for use in the practice of the present invention include antibiotic resistance genes, genes that enable cells to process metabolic intermediaries, and the like. Exemplary antibiotic resistance genes include genes which impart tetracycline resistance, genes that impart ampicillin resistance, neomycin resistance, hygromycin resistance, puromycin resistance, and the like.

Genes that enable cells to process metabolic intermediaries include genes which permit cells to incorporate L-histidinol, genes encoding thymidine kinase, genes encoding xanthine-guanine phosphoribosyl transferase (gpt), genes encoding dihydrofolate reductase, genes encoding asparagine synthetase, and the like.

As employed herein, the terms "subject organism" and "host" refer to the cell, tissue, organ or organism in need of transcriptional regulation of exogenous or endogenous nucleic acids. The subject organism can be mammalian or mammalian-derived cells or tissue. Exemplary mammals include: humans; domesticated animals, e.g., rat, mouse, rabbit, canine, feline, and the like; farm animals, e.g., chicken, bovine, ovine, porcine, and the like; animals of zoological interest, e.g., monkey, baboon, and the like, or a cell thereof. Alternatively, a subject organism can be a non-mammalian, preferably non-insect, such as a plant, fungus or other non-mammalian species, or a cell of such a non-mammalian species.

As employed herein, the term "ligand" (or ligand precursor) refers to a steroidal or non-steroidal substance or compound which, in its native state (or after conversion to its "active" form), binds to at least one of the protein units, or to the invention chimeric protein, thereby creating a ligand/functional entity complex, which in turn can bind an appropriate response element and activate transcription therefrom. Ligands function to modulate transcription of nucleic acid(s) maintained under the control of a response element. Such ligands are well known in the art.

In accordance with one aspect of the present invention, unless and until a suitable ligand is administered to the host, substantially no transcription of the desired exogenous nucleic acids occurs. Since ecdysteroids, for example, are not naturally present in mammalian, plant and fungal systems, and the like, if it is desired that transcription of a particular exogenous nucleic acid be under precise control of the practitioner, a chimeric protein containing an ecdysone receptor as one of the protein units and a suitable dimer partner therefore is used and the exogenous nucleic acid is put under the control of an ecdysone response element, i.e. a response element to which an activated ecdysone receptor binds in nature.

The terms "ecdysone" and "ecdysteroid" as interchangeably used herein, are employed in the generic sense (in accordance with common usage in the art), referring to a family of ligands with the appropriate binding and transactivation activity (see, for example, Cherbas et al., in *Biosynthesis, metabolism and mode of action of invertebrate hormones* (Ed. J. Hoffmann and M. Porchet), Springer-Verlag, Berlin, p 305-322. An ecdysone, therefore, is a compound which acts to modulate gene transcription for a gene maintained under the control of an ecdysone response element.

20-Hydroxy-ecdysone (also known as β -ecdysone) is the major naturally occurring ecdysone. Unsubstituted ecdysone (also known as α -ecdysone) is converted in peripheral tissues to β -ecdysone. Analogs of the naturally occurring ecdysones are also contemplated within the scope of the present invention. Examples of such analogs, commonly referred to as ecdysteroids, include ponasterone A, 26 iodoponasterone A, muristerone A, inokosterone, 26-mesylinokosterone, and the like. Since it has been previously reported that the above-described ecdysones are neither toxic, teratogenic, nor known to affect mammalian physiology, they are ideal candidates for use as inducers in cultured cells and transgenic mammals according to the invention methods.

Other phytoecdysteroids are also contemplated for use in the practice of the invention as ligands of receptors which recognizes ecdysone response elements. Such phytoecdysteroids are known in the art (J.H. Adler et al., *Lipids* 30(3):257-62, 1995). The biological effect of phytoecdysteroids in higher animals are also known (V.N. Syrov, *Eksp. Klin. Farmakol.* 57(5):61-6, 1994).

5 Non-steroidal ligands are also contemplated for use in the practice of the present invention as ligands of ecdysone response elements. For example, when a ligand not normally present in the cells of the host to be treated is desired (i.e., a ligand exogenous to the host), a hydrazine can be employed as the ligand, preferably a diacyl hydrazine. Such hydrazines include compounds that are readily available and/or are relatively inexpensive to manufacture. One such compound, tebufenozide, is a non-steroidal ecdysone agonist which is commercially available. This compound specifically targets lepidopteran species, including *Bombyx mori*. Tebufenozide has undergone extensive testing in animal hosts and has proved to be of very low toxicity to mammals and other non-insect species.

Additional exemplary hydrazines contemplated for use herein include 1,2-diacyl hydrazines (e.g., tebufenozide), N'-substituted-N,N'-disubstituted hydrazines, dibenzoylalkyl cyanohydrazines, N-substituted-N-alkyl-N,N-diaroyl hydrazines, N-substituted-N-acyl-N-alkyls, carbonyl hydrazines, N-aroyl-N'-alkyl-N'-aroyl hydrazines, and the like. Since it has been previously reported that the above-described diacyl hydrazines are neither toxic, teratogenic, nor known to affect mammalian physiology, they are ideal candidates for use as exogenic ligands (e.g. as inducers) in cultured cells and transgenic mammals according to invention methods.

Ligands, and formulations containing them, administered in a manner compatible with the route of administration, the dosage formulation, and in a therapeutically effective amount. The required dosage will vary with the particular treatment desired, the degree and duration of therapeutic effect desired, the judgment of the practitioner, as well as properties peculiar to each individual. Moreover, suitable dosage ranges for systemic application depend on the route of administration. It is anticipated that dosages between about 10 micrograms and about 1 milligram per kilogram of body weight per day will be used for therapeutic treatment.

25 An effective amount of ligand contemplated for use in the practice of the present invention is the amount of ligand (e.g., diacyl hydrazine(s)) required to achieve the desired level of transcription and/or translation of exogenous nucleic acid. A therapeutically effective amount is typically an amount of ligand or ligand precursor that, when administered in a physiologically acceptable composition, is sufficient to achieve a plasma concentration of the transcribed or expressed nucleic acid product from about 0.1 mg/ml to about 100 mg/ml, for example, from about 1.0 mg/ml to about 50 mg/ml, and preferably at least about 2 mg/ml and usually 5 to 10 mg/ml.

30 Ligand can be administered in a variety of ways, as are well-known in the art, i.e., by any means that produces contact between ligand and receptor peptide. For example, such ligands can be administered topically, orally, intravenously, intraperitoneally, intravascularly, and the like. The administration can be by any conventional means available for use in

conjunction with pharmaceuticals, e.g., by intravenous injection, either as individual therapeutically active ingredients or in a combination with other therapeutically active ingredients. Ligands contemplated for use in the practice of the present invention can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

5 In accordance with a particular embodiment of the present invention, pharmaceutically acceptable formulations, and kits thereof, comprising at least one ligand for an invention functional dimer, for example an ecdysteroid, and a pharmaceutically acceptable carrier are contemplated. In accordance with another aspect of the present invention, pharmaceutically acceptable formulations consisting essentially of at least one ligand and a pharmaceutically acceptable carrier, are contemplated. Pharmaceutical formulations of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting formulation contains one or more of the ligands of the present invention, as
10 an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications.

The ligand(s) may be compounded, for example, with the usual non-toxic, pharmaceutically acceptable carriers suitable for administration by oral, topical, nasal, transdermal, intravenous, subcutaneous, intramuscular, intracutaneous, intraperitoneal, intravascular, and the like means. Administration in the form of creams, lotions, tablets, dispersible powders, granules, syrups, elixirs, sterile aqueous or non-aqueous solutions, suspensions or emulsions, and the like, is contemplated. Exemplary
15 pharmaceutically acceptable carriers include carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. Such carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and/or perfumes may be used. The active compound (e.g.,
20 ecdysteroid as described herein) is included in the pharmaceutically acceptable formulation in an amount sufficient to produce the desired effect upon the process or condition of diseases.

Pharmaceutically acceptable formulations containing ligand(s) as active ingredient may be in a form suitable for oral use, for example, as aqueous or oily suspensions, syrups or elixirs, tablets, troches, lozenges, dispersible powders or granules, emulsions, or hard or soft capsules. For the preparation of oral liquids, suitable carriers include emulsions, solutions, suspensions, syrups, and the like, optionally containing additives such as wetting agents, emulsifying and suspending agents, dispersing agents, sweetening, flavoring, coloring, preserving and perfuming agents, and the like. Formulations intended for oral use may be
25 prepared according to any method known to the art for the manufacture of pharmaceutically acceptable formulations.

Tablets containing ligand(s) as active ingredient in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, potato starch or alginic acid; (3) binding agents such as gum tragacanth, corn starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay
30

disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, to form osmotic therapeutic tablets for controlled release.

5 In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the ligand is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the ligand is mixed with water or an oil medium, for example, peanut oil, liquid paraffin, or olive oil.

The pharmaceutically acceptable formulations may be in the form of a sterile injectable suspension. Suitable carriers include non-toxic parenterally-acceptable sterile aqueous or non-aqueous solutions, suspensions, or emulsions. This suspension
10 may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. They can also be manufactured in the form of sterile water, or some other sterile injectable medium immediately before use. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. They may be sterilized, for
15 example, by filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the formulations, by irradiating the formulations, or by heating the formulations. Sterile injectable suspensions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Buffers, preservatives, antioxidants, and the like can be incorporated as required.

Compounds contemplated for use in the practice of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These formulations may be prepared by mixing the drug with a suitable
20 non-irritating excipient, such as cocoa butter, synthetic glyceride esters of polyethylene glycols, which are solid at ordinary temperatures, but liquefy and/or dissolve in the rectal cavity to release the drug.

Pharmaceutically acceptable formulations containing suitable ligand(s) are preferably administered intravenously, as by injection of a unit dose, for example. The term "unit dose," when used in reference to a pharmaceutically acceptable formulation of the present invention, refers to a quantity of the pharmaceutical formulation suitable as unitary dosage for the subject, each
25 unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required diluent, i.e., carrier, or vehicle. It may be particularly advantageous to administer such formulations in depot or long-lasting form as discussed hereinafter.

Therapeutic compositions or pharmaceutically acceptable formulations containing suitable ligand are preferably administered intravenously, as by injection of a unit dose, for example. The term "unit dose," when used in reference to a
30 therapeutic composition of the present invention, refers to a quantity of ligand suitable as unitary dosage for the subject, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association

with the required diluent, i.e., carrier, or vehicle. It may be particularly advantageous to administer such compounds in depot or long-lasting form.

Suitable regimes for initial administration and booster shots are variable, but are typified by an initial administration followed by repeated doses at one or more intervals, by a subsequent injection, or other administration. Alternatively, continuous intravenous infusion sufficient to maintain concentrations in the blood in the ranges specified for *in vivo* therapies are contemplated.

In accordance with another embodiment of the present invention, there are provided methods for producing transgenic animals capable of prolonged and regulated expression of exogenous nucleic acid(s), said method comprising introducing into early stage embryos or stem cells of the animal:

- (i) a nucleic acid construct comprising a promoter and said exogenous nucleic acid(s) under the control of a regulatory element; and
- (ii) nucleic acid encoding an invention chimeric protein wherein the chimeric protein activates the regulatory element in the presence of a ligand for the functional dimer or represses the regulatory element independently of the presence of said ligand.

As used herein, the phrase "transgenic animal" refers to an animal that contains one or more expression constructs containing one or more exogenous nucleic acid(s) under the transcription control of an operator and/or hormone response element as described herein.

Methods of making transgenic animals using a particular nucleic acid construct are well-known in the art. When preparing invention transgenic animals, it is presently preferred that two transgenic lines are generated. The first line will express, for example, a chimeric protein as described above (e.g., VBEcR). Tissue specificity is conferred by the selection of a tissue-specific promoter (e.g., T-cell specific) that will direct expression of the chimeric protein to appropriate tissue. A second line contains a nucleic acid construct comprising a promoter and exogenous nucleic acid under the control of a response element, for example, an endogenous response element. Cross-breeding of these two lines will provide a transgenic animal that expresses an invention chimeric protein and the exogenous nucleic acid.

In a presently preferred embodiment, an invention transgenic animal contains one or more expression constructs containing nucleic acid encoding an invention chimeric protein and exogenous nucleic acid under the transcription control of a response element. Thus, with tissue specific expression of the chimeric protein as described above and timely ligand treatment, gene expression can be induced or repressed with spatial, dosage, and/or temporal specificity.

In accordance with yet another embodiment of the present invention, there are provided methods for modulating the transcription of an exogenous nucleic acid in a host containing:

(i) a nucleic acid construct comprising a promoter and said exogenous nucleic acid(s) under the control of a response element; and

(ii) nucleic acid under the control of an inducible promoter, said nucleic acid encoding an invention chimeric protein wherein the functional entity formed by the invention chimeric protein activates or represses the response element in the presence of a ligand for the entity; and

said method comprising introducing a ligand not normally present in the cells of the host and subjecting the host to conditions suitable to induce or repress expression of the invention chimeric protein.

In accordance with yet another embodiment of the present invention, there are provided methods for the expression of recombinant products detrimental to a subject organism, said method comprising:

transforming suitable cells in the organism with:

(i) a nucleic acid construct comprising a promoter and exogenous nucleic acid(s) which express the recombinant product under the control of a regulatory element that is not normally present in the cells of said organism, and

(ii) nucleic acid encoding an invention chimeric protein wherein the functional entity formed by the invention chimeric protein activates the regulatory element in the presence of a ligand for the functional entity;

growing said cells to the desired level in the substantial absence of the ligand; and

inducing expression of said recombinant product by administering to the organism a ligand, which, in combination with said entity, binds to said regulatory element and activates transcription therefrom.

Recombinant products detrimental to a host organism contemplated for expression in accordance with the present invention include any gene product that functions to confer a toxic effect on the organism. For example, inducible expression of a toxin such as the diphtheria toxin would allow for specific ablation of tissue (Ross *et al. Genes and Development* 7:1318-1324 (1993)), for example to create a new phenotype in the transgenic animal. Moreover, the numerous gene products that are known to induce apoptosis in cells expressing such products are contemplated for use herein (see, e.g., *Apoptosis, The Molecular Basis of Cell Death*, Current Communications In Cell & Molecular Biology, Cold Spring Harbor Laboratory Press, 1991).

In accordance with still another embodiment of the present invention, there are provided methods for modulating the transcription of nucleic acid(s) in an *in vitro* cellular system, wherein the method comprises administering to the cellular system an amount of ligand effective to modulate the transcription of the nucleic acid(s); wherein the ligand is not normally present in the cellular system and wherein the system comprises:

(i) a nucleic acid construct comprising a promoter and the nucleic acid(s) under the control of a response element; and

- (ii) nucleic acid encoding an invention chimeric protein,
wherein the functional entity formed by the invention chimeric protein activates or represses the regulatory element in the presence of a ligand for the ligand binding domain.

In accordance with yet another embodiment of the present invention, there are provided methods for the treatment of a host in need of gene therapy, said method comprising:

introducing into cells of said host:

- (i) a nucleic acid construct comprising a promoter and the exogenous nucleic acid(s) under the control of a response element;
- (ii) nucleic acid under the control of an inducible promoter, said nucleic acid encoding an invention chimeric protein,
wherein the functional dimer formed by the invention chimeric protein activates or represses the regulatory element in the presence of a ligand for the functional dimer, and
administering, to said host, an effective amount of ligand for the invention functional dimer.

Optionally, the cells can be obtained from the host, modified as above, and then reintroduced into the host organism. For example, the exogenous nucleic acid can be introduced directly into cells obtained from a donor (host or separate donor) and the modified cells are then implanted within the host organism. In a presently preferred embodiment, the transplanted cells are autologous with respect to the host. "Autologous" means that the donor and recipient of the cells are one and the same.

Cells can be modified by "in vivo delivery" of biological materials by such routes of administration as oral, intravenous, subcutaneous, intraperitoneal, intrathecal, intramuscular, intracranial, inhalational, topical, transdermal, suppository (rectal), pessary (vaginal), and the like. The exogenous nucleic acid may be stably incorporated into cells or may be transiently expressed using methods known in the art.

Modified cells are cultivated under growth conditions (as opposed to protein expression conditions) until a desired density is achieved. Stably transfected mammalian cells may be prepared by transfecting cells with an expression vector having a selectable marker gene (such as, for example, the gene for thymidine kinase, dihydrofolate reductase, neomycin resistance, and the like), and growing the transfected cells under conditions selective for cells expressing the marker gene. To prepare transient transfectants, mammalian cells are transfected with a reporter gene (such as the *E. coli* β -galactosidase gene) to monitor transfection efficiency. Selectable marker genes are typically not included in the transient transfections because the transfectants are typically not grown under selective conditions, and are usually analyzed within a few days after transfection.

The concept of gene replacement therapy for humans involves the introduction of functionally active "wild type" or "therapeutic" nucleic acids into the somatic cells of an affected host to correct a gene defect or deficiency. However, in order for gene replacement therapy to be effective, it must be possible to control the time and location at which gene expression occurs.

Genes that encode useful "gene therapy" proteins that are not normally transported outside the cell can be used in the invention if such genes are "functionally appended" to, or operatively associated with, a signal sequence that can "transport" the encoded product across the cell membrane. A variety of such signal sequences are known and can be used by those skilled in the art without undue experimentation.

5 Gene transfer vectors (also referred to as "expression vectors") contemplated for use herein are recombinant nucleic acid molecules that are used to transport nucleic acid into host cells for expression and/or replication thereof. Expression vectors may be either circular or linear, and are capable of incorporating a variety of nucleic acid constructs therein. Expression vectors typically come in the form of a plasmid that, upon introduction into an appropriate host cell, results in expression of the inserted nucleic acid.

10 Suitable expression vectors for use herein are well known to those of skill in the art and include recombinant DNA or RNA construct(s), such as plasmids, phage, recombinant virus or other vectors that, upon introduction into an appropriate host cell, result(s) in expression of the inserted DNA. Appropriate expression vectors are well known to those of skill in the art and include those that are replicable in eukaryotic cells and/or prokaryotic cells and those that remain episomal or those which integrate into the host cell genome. Expression vectors typically further contain other functionally important nucleic acid
15 sequences encoding antibiotic resistance proteins, and the like.

The amount of exogenous nucleic acid introduced into a host organism, cell or cellular system can be varied by those of skill in the art. For example, when a viral vector is employed to achieve gene transfer, the amount of nucleic acid introduced can be varied by varying the amount of plaque forming units (PFU) of the viral vector.

As used herein, the phrase "transcription regulatory region" refers to that portion of a nucleic acid or gene construct
20 that controls the initiation of mRNA transcription. Regulatory regions contemplated for use herein, in the absence of the non-mammalian transactivator, typically comprise at least a minimal promoter in combination with a regulatory element responsive to the ligand/receptor peptide complex. A minimal promoter, when combined with a regulatory element, functions to initiate mRNA transcription in response to a ligand/functional dimer complex. However, transcription will not occur unless the required inducer (ligand therefor) is present. However, as described herein certain of the invention chimeric protein heterodimers activate or
25 repress mRNA transcription even in the absence of ligand for the DNA binding domain.

As used herein, the phrase "operatively associated with" refers to the functional relationship of DNA with regulatory and effector sequences of nucleotides, such as promoters, enhancers, transcriptional and translational stop sites, and other signal sequences. For example, operative linkage of DNA to a promoter refers to the physical and functional relationship between the DNA and promoter such that the transcription of such DNA is initiated from the promoter by an RNA polymerase that specifically
30 recognizes, binds to and transcribes the DNA.

Preferably, the transcription regulatory region further comprises a binding site for ubiquitous transcription factor(s). Such binding sites are preferably positioned between the promoter and the regulatory element. Suitable ubiquitous transcription factors for use herein are well-known in the art and include, for example, Sp1.

Exemplary eukaryotic expression vectors include eukaryotic constructs, such as the pSV-2 gpt system (Mulligan *et al.*,
5 (1979) *Nature*, 277:108-114); pBlueSkript (Stratagene, La Jolla, CA), the expression cloning vector described by Genetics
Institute (*Science*, (1985) 228:810-815), and the like. Each of these plasmid vectors is capable of promoting expression of the
chimeric protein of interest.

Suitable means for introducing (transducing) expression vectors containing invention nucleic acid constructs into host
cells to produce transduced recombinant cells (i.e., cells containing recombinant heterologous nucleic acid) are well-known in the
10 art (see, for review, Friedmann, *Science*, 244:1275-1281, 1989; Mulligan, *Science*, 260:926-932, 1993, each of which are
incorporated herein by reference in their entirety). Exemplary methods of transduction include, e.g., infection employing viral
vectors (see, e.g., U.S. Patent 4,405,712 and 4,650,764), calcium phosphate transfection (U.S. Patents 4,399,216 and
4,634,665), dextran sulfate transfection, electroporation, lipofection (see, e.g., U.S. Patents 4,394,448 and 4,619,794),
cytofection, particle bead bombardment, and the like. The transduced nucleic acid can optionally include sequences which allow
15 for its extrachromosomal (i.e., episomal) maintenance, or the transduced nucleic acid can be donor nucleic acid that integrates into
the genome of the host.

In a specific embodiment, a gene transfer vector contemplated for use herein is a viral vector, such as Adenovirus,
adeno-associated virus, a herpes-simplex virus based vector, a synthetic vector for gene therapy, and the like (see, e.g., Suhr *et al.*
20 *Arch. of Neurol.* 50:1252-1268, 1993). Preferably, a gene transfer vector employed herein is a retroviral vector. Retroviral
vectors contemplated for use herein are gene transfer plasmids that have an expression construct containing an exogenous
nucleic acid residing between two retroviral LTRs. Retroviral vectors typically contain appropriate packaging signals that enable
the retroviral vector, or RNA transcribed using the retroviral vector as a template, to be packaged into a viral virion in an
appropriate packaging cell line (see, e.g., U.S. Patent 4,650,764).

Suitable retroviral vectors for use herein are described, for example, in U.S. Patents 5,399,346 and 5,252,479; and in
25 WIPO publications WO 92/07573, WO 90/06997, WO 89/05345, WO 92/05266 and WO 92/14829, each of which is hereby
incorporated herein by reference, in its entirety. These documents provide a description of methods for efficiently introducing
nucleic acids into human cells using such retroviral vectors. Other retroviral vectors include, for example, mouse mammary tumor
virus vectors (e.g., Shackelford *et al.*, (1988) *PNAS, USA*, 85:9655-9659), human immunodeficiency virus (e.g., Naldini *et al.*
(1996) *Science* 272:165-320), and the like.

30 Various procedures are also well-known in the art for providing helper cells which produce retroviral vector particles
that are essentially free of replicating virus. See, for example, U.S. Patent 4,650,764; Miller, *Human Gene Therapy*, 1:5-14,
1990; Markowitz, *et al.*, *Journal of Virology*, 61(4):1120-1124, 1988; Watanabe, *et al.*, *Molecular and Cellular Biology*,

3(12):2241-2249, 1983; Danos, *et al.*, *PNAS*, 85:6460-6464, 1988; and Bosselman, *et al.*, *Molecular and Cellular Biology*, 7(5):1797-1806, 1987, which disclose procedures for producing viral vectors and helper cells that minimize the chances for producing a viral vector that includes a replicating virus.

Recombinant retroviruses suitable for carrying out the invention methods are produced employing well-known methods for producing retroviral virions. See, for example, U.S. Patent 4,650,764; Miller, *supra* 1990; Markowitz, *et al.*, *supra* 1988; Watanabe, *et al.*, *supra* 1983; Danos, *et al.*, *PNAS*, 85:6460-6464, 1988; and Bosselman, *et al.*, *Molecular and Cellular Biology*, 7(5):1797-1806, 1987.

For example, in one embodiment, a modular assembly retroviral vector (MARV) can be utilized to express the invention chimeric protein and an antibiotic resistance gene. A "covector" (referred to herein as MARSHA) can be utilized to provide a nucleic acid construct comprising the promoter, the regulatory element and exogenous nucleic acid, and a second antibiotic resistance gene. The MARSHA vector carrying exogenous nucleic acid also has LTRs modified to promote high-level expression only in the presence of the invention chimeric protein encoded by MARV and exogenous ligand therefor. Co-infected primary mammalian cells can then be selected using both antibiotics, resulting in a cell population that is dependent on ligand for high-level expression of the exogenous nucleic acid.

By introducing all of the necessary regulatory machinery, plus exogenous nucleic acid, selectable markers, and nucleic acid encoding invention chimeric protein, e.g., into a MARV retrovirus, highly efficient insertion of exogenous nucleic acids into targeted cells can be achieved.

Thus, the above-described viral constructs address several important problems confronted in the use of retroviruses in application of therapeutic gene transfer strategies to a variety of human diseases. For example, the retroviral vectors of the invention are capable of prolonged gene expression under conditions where conventionally integrated retroviruses are no longer transcriptionally active.

To illustrate the invention chimeric protein FDs, EcR was used as the steroid/thyroid hormone nuclear receptor and multiple examples using either RXR or Usp as the dimer partner were constructed, with either the EcR or the dimer partner positioned at the amino terminus. The DNA binding, transactivation, and dimerization properties of these several FD variants were compared with the properties of native receptor complexes. The size of the ENU and ENR FDs prepared was in the range from about 135 to about 145 kD; whereas E alone had a size of 94 kD, as shown by Western blot analysis.

EcR-Usp and EcR-RXR FDs efficiently bind EcREs

The FDs were first examined for their ability to bind to target EcREs in response to ligand. FD proteins were extracted from transiently transfected human 293 cells that were either untreated or treated with 1 μ M mruA for 40 hours. To eliminate the possibility that certain of the FD constructs were translated with greater efficiency than others, which would lead to a false appearance of higher functional binding in comparative luciferase expression tests, β -galactosidase

expression of internal control plasmids cotransfected with FD constructs was performed. These tests indicated no significant differences in the transfection efficiency of individual FD constructs, indicating that the DNA binding differences observed for different FDs reflect intermolecular properties of the FDs themselves, not expression level. Accordingly, all reactions were normalized to an internal β -galactosidase control and total protein using the anti-EcR monoclonal antibody DDA2.7 (Koelle *et al.*, *supra*, 1991).

FD constructs with either 0 or 5 linker segments were assayed for their ability to bind labeled EcREs, as shown in Figure 2B. A prominent band co-migrating with band shifts for the separate dimer complexes (E + U and E + R) was observed in many lanes and indicated that some of the FDs formed functional DNA-binding internal dimers, referred to herein as "endodimers." For example, ROE, which is analogous to UOE, except for the substitution of U for R as the dimer partner, formed a clear endodimer band that was increased 4-fold by ligand, and demonstrated unequivocally a response to hormone. R5E, with a longer linker, had slightly decreased basal, and slightly increased ligand-stimulated, EcRE binding (5-fold) compared to that of ROE.

Constructs in which E is positioned at the N-terminus form endodimers and bind the EcRE probe an average of 10 times better than UNE constructs (Figure 2A). In addition, ENU constructs bind probe 80-150% more readily than even those other FDs with high-level EcRE binding, such as ESR, but display nearly complete insensitivity to ligand for formation of DNA-binding complexes. This effect was found to be substantially independent of linker length.

ENR FDs also demonstrate a greater affinity for the EcRE probe than do RNE constructs. However, unlike ENU constructs, ENR FDs have a high degree of dependence upon the presence of ligand for formation of endodimers.

The observation that ENU and ENR FDs bound probe better than either the RNE construct or the UNE construct prompted examination of whether the large 220 amino acid F domain of E (not found on R or U) accounted for this effect. Further EcRE probe binding studies performed utilizing several FDs having in-frame incremental deletions of EOR to NheI, PvuII, NarI, and BglII sites within the ecdysone receptor F domain (Figure 2B) showed that the deletions had a minimal effect on either response to ligand, or on binding to the EcRE probe. Only EOR- Δ BglII, in which the extreme C-terminal end of the hormone binding domain is removed, displayed significant loss of the shifted band. These results suggest that flexibility within the long EcR F domain is not the primary determinant of improved DNA binding by FDs containing a EcR at the N terminal. This was presumed to be the result of a perturbed ligand binding pocket as opposed to decreased flexibility of the dimer partners joined by a linker.

EcR-RXR and EcR-Usp FD Transactivation in Response to Ligand

The results shown in Figure 2 clearly indicate that the EcR-RXR and EcR-Usp FD chimeric proteins could both respond to hormone and interact with the response element for EcR; however, these tests provided no indication regarding the function of these proteins to transactivate responsive promoters and induce gene expression. To determine the ability of the FDs to transactivate responsive promoters and induce gene expression, the FDs and an EcRE-luciferase reporter plasmid

were co-transfected into 293 cells. The results of these studies revealed that the activity of the FDs was variably diminished compared to that of monomeric receptors.

It has also been discovered that the invention ENU FDs are constitutive repressors of transcription of a gene under the control of the corresponding steroid/thyroid hormone nuclear receptor's response element. For example, UNE constructs did not efficiently bind target EcREs (Figure 2), and predictably did not have a dramatic influence on expression of the E4-luc reporter plasmid. ENUs, on the other hand, although appearing to readily bind EcREs, were also unable to stimulate luciferase expression. To further confirm whether ENU proteins could bind target response elements, but had lost the capacity to transactivate, the ability of EOU to competitively block ligand-stimulated luciferase expression by monomeric receptors was tested. EOU elicited a dose-dependent inhibition of VE with endogenous dimer partner, whereas UOE had virtually no inhibitory influence (Figure 5A). At the lowest ratio tested, a 1:20 ratio of EOU to VE decreased stimulated expression of VE by 20%, while equimolar EOU blocked 80% of the response to ligand. At any concentration tested, UOE exhibited no suppressive effect on VE-mediated activation, and in fact, appeared to increase the stimulated level of expression by about 5% to about 15%. EOU had a similar influence on E without VP16 fusion (Figure 5B), and a lesser but measurable inhibitory effect on VE combined with separate exogenous Usp (Figure 5C). The 50% inhibition of the VE+U basal transactivation level may suggest that EOU binds the target EcRE about as well as complexes of the separate receptors. The plateau of the EOU suppressive effect at a 1:1 ratio with both E and E+U and the slightly increased stimulation at a 5:1 ratio of EOU to separate receptors indicate that, at higher concentrations, EOU can weakly transactivate in response to added ligand.

In the experiments described herein utilizing FDs containing various combinations of DEcR and BEcR with either RXR or Usp, the length of the linker was not observed to have a significant effect on any of the functions of the FDs. Surprisingly, even shortening of the large F-domain of *Drosophila melanogaster* EcR had little impact on ligand-responsive DNA binding of EcR FDs. Without restriction of the scope of the invention by any theoretical speculations, two possible explanations of this observation are offered. One possibility is that there is enough flexibility within the structure of the individual receptors that any deformation necessary to allow appropriate dimerization can be tolerated while preserving, in some cases, nearly complete activity. The second possibility is that the C-terminus of the 5' receptor naturally lies close in spatial proximity to the N-terminus of the 3' receptor such that the distance is easily spanned. In the absence of detailed structural data of intact nuclear hormone receptor dimers, neither explanation can be ruled out.

In the presence of ligand (i.e., MUA), RXR-containing FDs functioned similarly to monomeric ECR+RXR, but at approximately one-half of the maximum level of transactivation (for ESR). One likely explanation for this is that the FD constructs are expressed or translated less efficiently than the monomeric receptors as suggested by comparing the intensity of FD lanes to the E lane in a Western blot analysis. Although the level of absolute transactivation was halved, the relative induction of transcription by the ENR constructs, in particular, exceeded the relative induction of monomeric EcR and RXR.

To further address the partial or complete loss of transcriptional activation for FDs relative to the separate proteins, the powerful VP16 transactivating domain was coupled to the amino-termini of FDs or separate EcR to determine if this addition could restore lost transactivational capacity. While a linker containing 5 linker segments (65 amino acids) was sufficient to allow good DNA binding, it may not have allowed sufficient freedom of movement for other domains, including those responsible for transactivation, to fold or orient as they do in the native proteins. Length of the linkers in VESR and VESU was therefore increased in increments of 5 linker segments each to 10 and ultimately 20 linker segments (240 + 5 amino acids).

Addition of the VP16 activation domain to the amino terminus of the ENR FDs restored the full transactivation potential of the FDs relative to separate VP16-fused EcR, suggesting that addition of a strong transactivating domain overrides translational deficits caused by incorporating the receptor/dimer partner into a chimeric protein. However, VP16-ENU (VENU) chimeric proteins never exceeded 30% of the absolute level of transactivation of separate VE+U. One possible explanation is that some conformation constraint in the Usp half of the VENU constructs prevented the interaction of VENU with endogenous cofactors necessary for full high level expression. A second possibility is that increased spontaneous heterodimerization within ENU FDs results in a conformational alteration that decreases or blocks ligand binding, assuming that ligand plays a direct role in transactivation and not just dimerization.

High level VENU transactivation suggests that the very low level expression observed from unliganded ENR constructs in Figure 3 was due to transcriptional repression by bound ENR proteins. The addition of VP16 increased the basal VENU FD expression over 5-fold in comparison to separate VECR+RXR. This presumably reflected an increased level of spontaneous dimer formation of ENR FDs resulting from the forced proximity of the separate components by the linker. This phenomenon may not have been readily evident in the gel shift experiments as the result of the short transient period of interaction of the proteins with the DNA probes (< 30 minutes) compared to the duration with the responsive promoters in the transient transfection experiments (> 30 hours).

Heterodimer formation and DNA binding of FDs

Five different classes of interaction of protein units in the invention chimeric protein(s) (Figure 7) were predicted: 1) "disorganized", indicative of non-interaction by the individual receptor components; 2) "endodimer", indicating formation of functional dimers approximating the native heterodimer complex; 3) "trimer", indicating interaction with a separate monomeric partner, 4) "tetramer", indicative of two mutually cross-interacting chimeric proteins; or 5) "oligomers", representing chimeric proteins chain-interacting with each other. The data presented herein provides clear evidence that disorganized, endodimer, and trimer species were formed when the invention chimeric proteins contained two protein units (FDs), with endodimer formation predominating. Only the UNE constructs appeared to be largely disorganized, as evidenced by their apparent inability even to bind DNA with high affinity. All remaining FD classes showed abundant evidence of endodimer formation, although RNE constructs were noticeably weaker than constructs with EcR in the amino terminal position. The transient-transfection competition experiment (Figure 4) indirectly indicates that a high affinity monomeric

dimer partner, such as VUsp, can displace a weaker intramolecular RXR dimer partner to form a partially functional trimer species; however, such a monomeric, high affinity dimer partner was much less capable of displacing an intramolecular Usp under the same circumstances. The lower affinity VRXR monomeric dimer partner was unable to displace to any significant degree either Usp or RXR as an intramolecular dimer partner in an invention FD fusion protein.

5 Evidence of formation of higher order constructs, such as tetramers or oligomers, in gel shift assays is scant, but may be suggested in lanes of the gel shift assay with UNE and RNE constructs. Although band shifts were weak, UNE (and unliganded RNE) constructs had slightly intensified bands of higher molecular weight than the corresponding size of the endodimer bands. The faint but detectable high molecular weight shift bands observed for FDs in some lanes of the assays suggest tetramer and oligomer formation, presumably through cross interaction of the ecdysone receptor component of one
10 FD with the dimer partner unit of another. These results, coupled with the results of competition experiments using superphysiological levels of competing dimer partner, suggest, in any event, that multimerization is relatively rare and is likely to occur, at even low levels, only with those FDs that have decreased capacity for endodimer formation.

These data further support the supposition that proximity to dimer partner (i.e., as in invention chimeric protein(s)) not only limits dimer partner preference, but also increases the ease of dimer formation and DNA binding for some of the
15 fusion constructs relative to monomeric receptors. For example, ENU constructs displayed high-level complex formation with the EcRE probe (a 1.1- and 0.9-fold increase for EU and E5U, respectively) even in the absence of ligand, while separate EcR and Usp required ligand for maximal complex formation. ENR constructs, on the other hand, still retained much of their original ligand dependence, indicating that dimer partner proximity is not the sole, or perhaps even most important, determinant of dimer formation.

20 The degree to which FDs interact with external receptors to form a trimer complex was indirectly examined in the studies showing their interaction with high levels of competing VP16-fusion dimer partners and the resulting effect on transactivation of the E4-luc reporter. In these studies, monomeric VRXR was unable to enter the FD complex of any construct, suggesting that the EcR component of FDs much prefers a linked dimer partner of either high or low affinity to a separate low affinity dimer partner. VUsp, on the other hand, had a comparatively smaller effect on transactivation induced
25 by the E5U construct, than on E5R, indicating that the EcR protein in E5U preferentially dimerizes with the linked Usp, while the RXR dimer partner of E5R may enter a complex with monomeric VUsp.

In summary, the results of the studies described herein indicate that selected chimeric proteins of steroid/thyroid hormone nuclear receptors with appropriate dimer partners can retain most of the primary characteristics of the native complex: binding of ligand, recognition and binding of cognate response elements, and, in some cases, ligand-stimulated
30 transactivation of responsive promoters. Subsets of the constructs prepared displayed varying degrees of these characteristics. The R/UNE proteins characteristically exhibited low DNA binding and transactivation capacity while the ENR/U proteins uniformly demonstrated wild-type or superior EcRE binding and variable capacity to transactivate, resulting in properties ranging from constitutive repression to essentially wildtype, ligand-responsive transactivation.

The invention herein provides the advantage that, for many studies in cultured cells or transgenic animals, invention FDs will allow the examination of specific heterodimer pairs with much decreased potential for contamination with exterior dimer partners, such as those endogenously produced in the test cell or animal. This may be of particular assistance in examining the function of specific RXR subtype combinations, or even for further studying the potential for Usp-Usp interactions.

The invention herein provides the further advantage that specific heterodimer pairs can be examined by their introduction into the system as a single chimeric protein, e.g., as a fusion protein, rather than by separate introduction of two constructs.

In addition, studies described in the Examples herein indicate that many of the combinations may have unique properties of ligand independence or repression that may have significance to their application for therapeutic purposes. For example, certain of the invention chimeric proteins that transactivate gene expression may be useful as a "gene switch," for modulating expression of an exogenous gene in a mammalian system or in plants, fungi and other non-mammalian species. When the FDs transactivate the response element-containing promoter (e.g., in the presence of ligand), the exogenous gene is switched on; when the FDs repress the promoter, the exogenous gene is switched off.

In nature, dimers of nuclear hormone receptors are unstable and, hence, are not useful in x-ray crystallography studies to determine structure. Because of the demonstrated stability of the invention FD heterodimers, they may be advantageously used in the preparation of crystals for x-ray diffraction studies for use in rational design of ligands to develop new steroids, insecticides, steroid antagonists, and the like, as described hereinbelow. Crystal structure may also permit deduction of the structure of ligands for orphan receptors. It is also contemplated that such crystals of the invention FDs can be used for preparation of antibodies that react with the heterodimers using methods known in the art.

In accordance with another embodiment of the present invention, there are provided isolated protein crystals suitable for x-ray diffraction analysis of a purified invention chimeric protein. In alternative embodiments, the crystal may be obtained of a ligand bound to a purified chimeric protein so as to form a chimeric protein-ligand complex, or a crystal may be obtained of a putative response element bound to purified fusion protein or fusion protein ligand complex as described herein. The invention additionally contemplates a set of x-ray diffraction crystal coordinates obtained by x-ray diffraction of any such invention isolated protein crystals.

A variety of methods are known in the art for purifying proteins and obtaining crystals of the purified proteins, for example growing crystals in microgravity and/or by vapor diffusion (D.R. Davies and D. M. Segal, *Meth. Enzymol.* 22:266, 1971). Crystals of purified proteins can also be obtained commercially. To aid in the purification of the invention fusion proteins, it is recommended to add a His tag to the amino terminus of the fusion protein, as is known in the art and described in Example 6 herein. Addition of such a His tag does not interfere with dimerization of the invention fusion proteins.

In accordance with still another embodiment of the present invention, there are provided methods for identifying potential ligand(s) for member(s) of the steroid/thyroid hormone nuclear receptor superfamily utilizing a set of atomic coordinates obtained by x-ray diffraction analysis of an invention purified protein crystal. The invention assay method comprises creating a three-dimensional structure of a chimeric protein formed into a functional entity (i.e., by dimerization of dimerization domains contained therein) as defined by the atomic coordinates obtained by x-ray diffraction studies, employing the three-dimensional structure to design or select the potential ligand; synthesizing the potential ligand; and then contacting the potential ligand with an invention functional entity in the presence of a response element operatively linked to a marker protein under conditions suitable for causing expression of the marker protein to determine the ability of the potential ligand to transactivate expression of the marker protein. The potential ligand can be designed de novo or designed from a ligand.

Methods for obtaining a set of atomic coordinates of a protein crystal using x-ray diffraction and for creating a three-dimensional model of a protein from such a set of atomic coordinates are known in the art. Such procedures are disclosed, for example, in U. S. Patent No. 5,856,116, which is incorporated herein by reference in its entirety. For example, x-ray data sets can be collected on a R-axis IIC image plate system and/or on a 2.2 Å Synchrotron data set for refinement of the three-dimensional structure (i.e., the model). Then, the data can be collected at Cornell High Energy Synchrotron Source ("CHESS") on a charge-couple device and reduced to structure factor amplitudes using the Denzo Software Package (Denzo: An Oscillation Data Processing Program For Macro Molecular Crystallography, ©1993, Daniel Gewirth, Yale University). Oscillation photographs can be integrated and reduced to structure factor amplitudes using software supplied by the manufacturer (Molecular Structures Corp., Dallas, Tex.).

Refined heavy atom parameters can be used to compute multiple isomorphous replacement phases. Solvent flattening and phase extension (CCP4-Collaborative Computing Project No. 4, A Suite of Programs for Protein Crystallography; Daresbury Laboratory, Warrington, WA4 4AD, U.K. (1979)) can be used to improve the map and allow identification of some of the residues in the protein core. Cycles of model building (Quanta, version 4.0b, Molecular Simulations Inc., Burlington Mass.), positional refinement (Brunger, A. T., *J. Acta Cryst.*, A46:46-57, 1990); Brunger, A. T. et al., *J. Acta Cryst.*, A46:585-93, 1990) and phase combination (CCP4-Collaborative Computing Project, *supra*) can be carried out until the switch to phases calculated from the model can be made. Refinement against 16 °C., 2.2 Å data can be continued to allow the more difficult loop regions of the protein to be constructed.

The invention will now be described in greater detail by reference to the following non-limiting examples.

EXAMPLE 1

Design of ecdysone receptor-Usp/RXR functional dimers

Two classes of chimeric proteins were constructed as fusion proteins to study the activity of EcR-Usp/RXR functional dimers. In one class, EcR is at the N-terminus of a fusion protein, and in the other class the binding partner (either

Usp or RXR) is at the N-terminus (Figure 1). To facilitate formation of the functional dimers and allow for insertion of polypeptide linkers between the receptor and its binding partner in the fusion protein, a 5 amino acid bridge that also encodes the restriction endonuclease site for SfiI was inserted between the two open reading frames (ORFs).

A double stranded SfiI compatible oligonucleotide encoding the amino acid sequence GPGGSGGGSGT (SEQ ID NO:17) was designed to provide a high degree of predicted flexibility while attempting to minimize repetitive sequence within the oligonucleotide. This nucleotide sequence incorporated the SfiI site at the 5' end of the insert to allow for ease in increasing the number of linker segments within a previously existing construct. By phosphorylating the 36-base-pair double stranded oligonucleotides and ligating them into SfiI digested FD plasmid templates, FDs were produced with peptide linkers of variable length that increased by 12 amino acid increments.

10 Construction of fusion proteins containing the ecdysone receptor.

Figure 1 shows the schematically fusion protein functional dimer constructs R/U(N)E and E(N)R/U. Construction of the invention fusion proteins began with modification of the N and C termini of human RXR α , dmUsp and dmEcR ORFs subcloned into the cloning vector SK-NBN (pBSK with a modified polylinker). An SfiI site was inserted at either end of each receptor, in-frame, by PCR mutagenesis.

15 For the hRXR N-terminal SfiI site, the primer in the 5' direction was GTAGAATTCGGCCAACAGGGCCCATGGACACAAACATTTC (SEQ ID NO:18); and the primer in the 3' direction was GATGGGGGAGCTCAGGGTGC (SEQ ID NO:19).

For the C-terminal SfiI site, the primer in the 5' direction was GGAGAGCTCGAGGCCTACTGCA (SEQ ID NO:20); and the primer in the 3' direction was ACCATCGATTACAGGGCCCTGTTGGCCCGTGCGGCGCCTC (SEQ ID NO:21).

20 For the dmusp N terminal SfiI site, the primer in the 5' direction was GTAGAATTCGGCCAACAGGGCCCATGGACAACTGCGACCAG (SEQ ID NO:22); and the primer in the 3' direction was CAGCACGTGGACCATTGACA (SEQ ID NO:23).

For the C-terminal SfiI site, the primer in the 5' direction was GGAGAGCTCTTTCTCGAGCAGCTG (SEQ ID NO:24); and the primer in the 3' direction was ACCATCGATTACAGGGCCCTGTTGGCCCGTCCAGTTTCATCGCCA GGCCG (SEQ ID NO:25).

For the ecdysone receptor N-terminal SfiI site, VP16 sequences were fused in frame to the NcoI site approximately 200 base pairs into the ecdysone receptor ORF, creating an SfiI site at the VP16-ecdysone receptor boundary.

For the VP 16 insertion site, the primer in the 5' direction was CATAAGCTTATGGGACAGACACTGATGGGACGGCCC (SEQ ID NO:26) and the primer in the 3' direction was CAGAGACCATGGGCCCTGTTGGCCCCCACC (SEQ ID NO:27).

For the ecdysone receptor C-terminus insertion site, the primer in the 5' direction was TTACCGCTAGCTCCACCA (SEQ ID NO:28); and the primer in the 3' direction was GTAGATATCAGGGCCCTGTTGGCCCAGTCGTCGAGT (SEQ ID NO:29). All primer sequences are written 5' to 3'.

For VP16 (S.J. Triezenberg *et al.*, *Genes Dev.*, 2:718-729, 1988) fusion to RXR and Usp, the VP16 sequence region was removed from VE using the SfiI site at the 3' boundary of VP16 sequence for fusion of the 260 base pair VP16 fragment into the N-terminal compatible SfiI site of previously modified RXR and Usp ORFs. All fusion receptor variants were originally produced by insertion of both ORFs at the central SfiI site. Linker segments with SfiI compatible overhangs were produced by annealing two linker-encoding oligonucleotides having the sequence GGGCCAGGAGGTGGCTCCGGGGGAGGTTAGGCACA (SEQ ID NO:30) in the 5' direction, and the sequence GCCTGAACCTCCCCGGAGCCACCTCCTGGCCCTGT (SEQ ID NO:31) in the 3' direction.

EcR F-domain deletion constructs were produced by inserting an in-frame polylinker upstream of the SfiI-N-terminal modified RXR for reception of compatible F-domain deleted ecdysone receptor fragments. The polylinker in the 5' direction, AAGCTTGAGAGATCTGGGACGGCGCCCCGGGGCTAGCGGGCCAACA (SEQ ID NO:32) encoded (from Bgl II) the peptide sequence IWDGAPGAS (SEQ ID NO:33) and restriction sites Hind III-Bgl II-Nar I-Sma I-Nhe I with an SfiI compatible 3' end. Hind III-Bgl II, Hind III-Nar I, etc. fragments of the ecdysone receptor were inserted into this polylinker for fusion of F-domain deletions to RXR. Figure 2B shows schematically the F-domain deletion constructs of EOR made by this procedure.

PCR reactions for production of receptor mutants were performed using 100 ng plasmid template, 500 ng of each primer, and reaction conditions outlined by the manufacturer for Pwo (Boehringer Mannheim) high-fidelity polymerase. A program of 1 min, 94°C/1 min, 45°C/1 min, 72°C/1 min, for 20 cycles was used for production of all PCR products used. For constructs containing multiple repeat linker segments, fusion receptors were linearized by SfiI digest, and linker segment oligonucleotides, kinased to allow multiple tandem insertions, were ligated into the site by standard methods. Inserted linker segment repeats of between 0 and 5 linker segments were found by restriction endonuclease digest followed by sizing on 3% agarose gels. For the studies reported here, the minimum linker length contained only the 5 amino acid fusion bridge (signified herein by linker segment designation "0") and the maximum was 245 amino acids (including a five amino acid fusion bridge) (signified herein by linker segment designation "20").

Plasmids from clones of interest were prepared on a large scale for use in transfection and other analysis including confirmatory sequencing of constructs. All receptors were subcloned into vector LNCX (A.D. Miller, GenBank Acc. No. M28247) (with an extended polylinker) for use in transfection.

EXAMPLE 2

Transfection of FD constructs.

For quantitative transactivation analysis, transfections were performed in triplicate in 24-well plates by calcium-phosphate co-precipitation with 100 ng of an individual receptor, the reporter plasmid E4-luc, and pCH110 (SV40- β -

galactosidase) as an internal control. Briefly, the reporter plasmid, E4-luc, was constructed of 4-tandem EcREs inserted upstream of a thymidine kinase gene minimal promoter directing luciferase expression. EcRE oligonucleotides were as described by Thomas *et al., supra* (1993) with BamHI/BglII compatible ends. 1 μ M ligand was added at the time of transfection, and the cells were harvested for luciferase assay 40 hours later. Harvested cell extracts were split, and one part was analyzed in a luminometer for luciferase activity and the other part was analyzed for β -galactosidase activity using an orthonitrophenyl galactoside assay by standard methods. Luciferase levels were normalized to β -galactosidase values to correct for slight differences in transfection efficiency.

Preparation of the invention fusion protein FDs for gel shift analysis by transient transfection into 293 cells was as follows: 300 ng of individual receptor plasmids and 100 ng pCH110 internal control plasmid were cotransfected into 293 cells at 60% density in Costar 6-well plates. One well of each group was treated with 1 μ M murA as ligand at the time of transfection. 40 hours later, extracts of transfected 293 cells were made by scraping the cells from a well into a low volume of phosphate buffered saline, pelleting the cells, resuspending them in 200 μ l 5X gel shift buffer (Yao *et al., supra* 1992), and sonicating with a Kontes cell disrupter for three 10-sec. bursts at output level 30. The extracts were then centrifuged to clear the lysate and the protein was quantified. Extract volumes were adjusted with buffer to a concentration of 1 mg/ml and frozen at -70°C until use. β -galactosidase activity was assayed as above to determine relative transfection efficiency of each well.

EXAMPLE 3

Gel mobility shift analysis.

Comparative gel mobility shift analyses of FDs with control *in vitro* translated receptor complexes were performed using double stranded EcRE probes and labeled by Klenow fill using 32 P-dCTP and cold dGAT by standard methods. *In vitro* translated proteins used as controls were produced using the T3/T7 TNT (Promega) transcription/translation system following the manufacturer's protocol. *In vitro* translated proteins were qualitatively examined by 5% SDS-PAGE using protocols as described (J. Sambrook *et al. Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, New York, 1989) to ensure the presence of full-length products of the proper molecular weight. Reaction conditions for protein-probe interaction and gel electrophoresis were essentially identical to those disclosed in Yao *et al., supra* 1992. However, to improve comparison between samples, reaction mixtures (including dimer partners and probe) were prepared as a cocktail and distributed equally to individual tubes with receptor proteins. β -galactosidase assay indicated that all samples were essentially equivalent, so equal volumes (10 μ l) of extract were used in each reaction in a final reaction volume of 30 μ l. The reactions were allowed to proceed at 23°C for 5 minutes at which time ligand or vehicle was added and the reaction allowed to continue for 20 additional minutes. Band volumes were quantified using laser scanning densitometry.

Western blot analysis

6-well plates of 293 cells transfected with 2 μ g of receptor construct and 100 ng of pCH110 were harvested in PBS and lysed by three rounds of freezing and thawing. β -galactosidase assay of lysates indicated equivalent transfection efficiency for all constructs so equivalent protein (7.5 μ g) was loaded and run on a 12.5% SDS-PAGE gel and transferred to nitrocellulose by standard methods (*Sambrook et al., supra* 1989). The transferred filter was incubated with the anti-EcR monoclonal antibody DDA2.7 (*Koelle et al., supra* 1991) at a 1/1000 dilution at 4°C for 48 hours. After washes, anti-mouse IgG (1/5000) was added for 1 hour, washed away, and the blot processed for chemiluminescence and exposed to film.

An autoradiogram of FDs and controls treated either with control vehicle or with 1 μ M of murA as ligand was made with markers indicating endodimer FD or wild type receptor-binding complex band shifts. E + U and E + R were control lanes of *in vitro* translated proteins for sizing of endodimer band shifts. Figure 2A is a graph that quantifies endodimer-sized band volumes obtained from the autoradiogram.

A prominent band co-migrating with band shifts for the separate dimer complexes (E + U and E + R) was observed in many lanes and indicated that some of the FDs formed functional DNA-binding internal dimers that we designate "endodimers." UOE displayed a barely detectable endodimer band that was perceptibly increased (2-fold) in intensity by the presence of ligand (Figure 2B). The addition of 5 linker segments in USE appeared to amplify the overall intensity of the shift, but still displayed minimal response to ligand. UNE constructs displayed faint bands above the weak endodimer band-shift that were equally as intense. These bands were occasionally visible but were proportionally less intense than the endodimer band shift of other FDs described below. ROE, which is analogous to UOE but with substitution of U for R, formed a clear endodimer band that was increased 4-fold by ligand (Figure 2B), and unequivocally demonstrated FD responds to hormone. R5E, with a longer linker, had slightly decreased basal, and slightly increased ligand-stimulated, EcRE binding (5-fold) compared to ROE. The higher molecular weight shift bands observed in UNE lanes were not visible in ligand-treated R5E lanes (Figures 2A).

ENU constructs indicated that FDs in which E was positioned at the N-terminus formed endodimers and bound the EcRE probe an average of 10 times better than UNE constructs. ENU constructs bound probe 80-150% more readily than even other FDs with high-level EcRE binding (i.e., E5R, discussed below), but displayed nearly complete insensitivity to ligand for formation of DNA-binding complexes. Like UNE FDs, the longer linker length of E5U did not significantly increase the binding to EcRE or responsiveness to murA, relative to EOU (Figures 2A and 2B). ENR constructs, like ENUs, also demonstrated a greater affinity for the probe than the reversed constructs (Figure 2A). Unlike ENU constructs, ENR FDs had a high degree of ligand dependence for endodimer formation. E5R displayed a slightly decreased shift from the rate of basal transcription, and a slightly elevated ligand-stimulated shift (11-fold relative induction) in comparison to EOR (7-fold), much like ROE and R5E. Non-transfected cells, or cells transfected only with E, displayed no detectable shift even after prolonged exposure. At concentrations of protein higher than those used in these gel-shift reactions, a shift of E in combination with

endogenous RXR was observed. Separate experiments also confirmed that FDs specifically bound EcREs and not unrelated control probes that included thyroid hormone response elements.

Figure 3 shows relative luciferase expression of FD constructs with or without 1 μ M *murA*. The results of these studies are summarized in Table 1 below and show repression of monomeric receptors and monomeric dimer partners by EOU and UOE FDs.

TABLE 1

	UOE	ROE	USE	RSE	EOU	EOR	ESU	ESR	E	E+U
-Lig/E ₄	0.75	0.18	0.52	0.25	0.17	0.21	0.41	0.46	1.08	1.74
+Lig/E ₄	0.55	1.75	0.69	1.50	0.40	3.39	0.62	3.89	7.72	8.34
Rel. Ind.	0.7	9.7	2.7	6.0	2.4	16.2	1.6	8.4	7.1	4.8

-Lig/E₄ = luciferase activity in cells transiently co-transfected with FDs and monomeric receptors vs. reporter only without ligand
 +Lig/E₄ = luciferase activity in cells transiently co-transfected with FDs and monomeric receptors vs. reporter only with ligand
 Rel. Ind. = relative induction of individual receptor groups

As shown in Table 1, UNE and ENU constructs either did not stimulate luciferase expression or appeared to actually function as repressors of basal transcription. EOU in the absence of ligand, for instance, reduced E₄-luc transcription to only 17% of the basal expression level. RNE and ENR constructs, by comparison, functioned much more like separate E + R, although both the basal and induced levels were proportionally decreased relative to the monomeric receptors. As might be predicted from the mobility shift experiments, ESR provided the closest profile to the monomeric (i.e., wild type) separate receptors, having approximately 50% of the E + R induced expression level. By contrast, both EOR and ESR, however, had greater relative inductions than separate E + R (16.2- and 8.4-fold, respectively, versus 7.1-fold).

EXAMPLE 4

Addition of the potent VP16 transactivation (τ) domain to the N-terminus of FD constructs was used to further examine transactivation by FDs. To test the possibility that distortion of the endodimer by a short linker (0 linker segments) contributed to inhibited transactivation, the number of linker segments in the linker between the units in the invention fusion proteins was expanded to a maximum of 20 linker segments for ENR and ENU variants. As shown in Figure 4A, addition of a VP16 τ domain to either the E monomer (VE) or to FDs (VENR or VENU) resulted in a 12 to 15-fold overall increase in luciferase expression. These VENR FDs containing linkers of variable length produce a stimulated level of transcription virtually identical to separate VE protein, suggesting that augmentation of ENR proteins with VP16 τ domain compensated for any loss in transactivation resulting from the fusion of the receptor and dimer partner into the invention fusion proteins.

Notably, however, the level of basal, induced expression was increased 7 to 8-fold over monomeric receptors. This resulted in a dramatic decrease in the relative fold induction, from 27.8-fold for separate VE to 4.1 to 5.4-fold for FDs (Figure 4A). In addition, the increase from a 5 amino acid linker to a 245 amino acid linker had little effect on either basal or activated VERN transactivation with the exception of a subtle decrease in both levels in the FDs having the longer 125 (10 linker segments) and 245 amino acid (20 linker segment) linkers. As shown in Figure 4B, VENU constructs displayed neither the basal nor induced level of expression of separate VE + U, even though the overall level of transactivation was significantly increased relative to E + U complexes without a heterologous transactivating domain. Like the VERN proteins, the addition of increased linker segments to the VENU constructs had a minimal effect on basal or induced transcriptional activation.

EXAMPLE 5

To elucidate the propensity of fusion protein partners to dimerize with each other over other monomeric suitable dimer partners, the influence of monomeric dimer partners on FD transactivation properties was assayed. In the transient transfection experiments shown in Figure 6, R and U proteins with N-terminal VP16 fusions (VR and VU, respectively) were utilized to probe E5U and E5R promiscuity. E5R and E5U constructs were used because previous experiments suggested that they displayed properties that were the most similar to monomeric (i.e., wild type) receptors. When both E5R and E5U constructs were cotransfected into 293 cells in equimolar quantities along with the E4-luc reporter, VR cotransfection was not observed to significantly influence either E5U or E5R function, even though VR was found to augment E-mediated transactivation alone by > 5-fold either with or without ligand (Figure 6). VU, on the other hand, delectably interacted with E5R, and to a lesser extent with E5U. Ligand-dependent transactivation was observed for E5U + VUsp at approximately 10% of the ligand-stimulated level of VUsp with E, whereas E5R + VUsp activated to nearly 50% of the VUsp + E level. VR and VU alone had no influence on E4-luc expression either with or without murA.

EXAMPLE 6

Using a modification of the method for constructing invention fusion proteins described above in Example 1, fusion proteins were constructed having a *Bombyx* ecdysone receptor (BEcR) in the amino terminal half of the fusion protein, a linker bridge of 5 amino acids, and either RXR (BEOR) or Usp (BEOU) as the dimer partner placed at the C-terminal half of the fusion protein. To facilitate cloning, the BEcR amino acid sequence in each of these fusion proteins was augmented at the C-terminal end with amino acids 650-878 from the *Drosophila melanogaster* ecdysone receptor. Similar constructs were made wherein a His tag was positioned at the amino terminus of the fusion protein to facilitate purification of the fusion protein (HisBEOR and HisBEOU, respectively).

Gel mobility shift assays using tebufenozide and MurA as ligand were conducted as described in Example 3 above to determine whether functional dimers formed from the BEOR and BEOU fusion proteins. The results of these assays showed the both BEOR and BEOU dimerize and constitutively bind target DNA irrespective of the presence of ligand. When

the study was repeated using HisDEOR, HisBEOR and HisBEOU, it was determined that the His tag does not effect the ability of these fusion proteins to bind target DNA.

It will be apparent to those skilled in the art that various changes may be made in the invention without departing from the spirit and scope thereof, and therefore, the invention encompasses embodiments in addition to those specifically disclosed in the specification.

5

WHAT IS CLAIMED IS:

1. A chimeric protein comprising:
at least two functional protein units, wherein each functional protein unit comprises the dimerization
domain of a member of the steroid/thyroid hormone nuclear receptor superfamily, and
an optional linker interposed therebetween,
5 wherein the at least two protein units form a functional entity.
2. The chimeric protein according to claim 1 wherein the entity is an endodimer.
3. The chimeric protein according to claim 1 wherein each protein unit comprises a ligand binding domain, an
10 optional hinge domain, and an optional DNA binding domain.
4. The chimeric protein according to claim 3 wherein the functional entity is an endodimer.
5. The chimeric protein according to claim 1 wherein at least one member is non-mammalian.
15
6. The chimeric protein according to claim 5 wherein the at least one member is from an insect species.
7. The chimeric protein according to claim 1 wherein at least one functional protein unit comprises the
dimerization domain of an ecdysone receptor.
20
8. The chimeric protein according to claim 7 wherein the ecdysone receptor comprises the dimerization
domain of a *Drosophila* ecdysone receptor.
9. The chimeric protein according to claim 7 wherein the ecdysone receptor comprises the dimerization
25 domain of a *Lepidoptera* ecdysone receptor.
10. The chimeric protein according to claim 7 wherein the ecdysone receptor comprises the dimerization
domain of a *Bombyx* ecdysone receptor.
- 30 11. The chimeric protein according to claim 5 wherein at least one functional protein unit comprises the
dimerization domain of the *ultraspiracle* protein.
12. The chimeric protein according to claim 1 wherein at least one member is non-mammalian.

13. The chimeric protein according to claim 1 wherein at least one functional protein unit comprises the dimerization domain of the retinoid X receptor.

14. The chimeric protein according to claim 1 wherein the protein units are independently selected from the group consisting of glucocorticoid receptors, mineralocorticoid receptors, estrogen receptors, progesterone receptors, androgen receptors, Vitamin D3 receptors, retinoic acid receptors, retinoid X receptors, peroxisome proliferator-activated receptors, thyroid hormone receptors, and steroid and xenobiotic receptors, farnesoid X receptor, pregnenolone X receptor, liver X receptor, and BXR.

15. The chimeric protein according to claim 1 wherein the linker contains from about 5 to about 245 amino acids.

16. The chimeric protein according to claim 15 wherein the linker contains from about 53 to about 125 amino acids.

17. The chimeric protein according to claim 15 wherein the linker comprises glycine, proline, serine, alanine and threonine residues.

18. The chimeric protein according to claim 15 wherein the chimeric protein is a chimeric protein and the linker comprises the amino acid sequence of SEQ ID NO:15.

19. The chimeric protein according to claim 3 wherein one or more protein units further comprise a C-terminal domain.

20. The chimeric protein according to claim 3 wherein the DNA binding domains of one or more protein units comprise 66 to 68 amino acids, including 9 cysteines.

21. The chimeric protein according to claim 3 wherein the hinge domain of one or more protein units is the *Bombyx* hinge domain.

22. The chimeric protein according to claim 1 wherein one or more protein units further comprise an activation domain.

23. A polynucleotide encoding a chimeric protein according to claim 1.

24. A cell containing a polynucleotide according to claim 23.

25. The cell according to claim 24 wherein the cell is mammalian.

5 26. A method for modulating the expression of an exogenous gene in a subject organism containing:

1) a chimeric protein according to claim 1, and

2) a DNA construct comprising the exogenous gene under the control of a response element with which the chimeric protein interacts,

10 said method comprising administering to the subject an effective amount of an exogenous ligand for at least one functional unit of the chimeric protein.

27. The method according to claim 26 wherein the chimeric protein is encoded by a DNA construct.

15 28. The method according to claim 26 wherein the subject organism is a plant, an animal, a fungus or a bacterium.

29. The method according to claim 26 wherein the subject organism is mammalian.

20 30. The method according to claim 28 wherein at least one of the protein units is non-mammalian.

31. The method according to claim 29 wherein at least one of the protein units is from an insect species.

32. The method according to claim 26 wherein the modulation is ligand-dependent repression.

25 33. A method for modulating the expression of an exogenous gene in a subject organism containing a DNA construct comprising the exogenous gene under the control of a response element,

said method comprising administering to the subject an effective amount of a chimeric protein according to claim 1,

30 wherein the modulation is independent of ligand.

34. The method according to claim 33 wherein the modulation is ligand independent activation.

35. The method according to claim 33 wherein the modulation is ligand independent repression.

36. A method for modulating the expression of an gene in a subject organism containing a chimeric protein according to claim 1,

said method comprising introducing to the subject an effective amount of a DNA construct comprising the gene under the control of a response element,

5 wherein the response element is responsive to the chimeric protein and wherein the modulation is independent of ligand for the chimeric protein.

37. The method according to claim 36 wherein the gene is exogenous.

10 38. The method according to claim 36 wherein the modulation is ligand independent activation.

39. The method according to claim 36 wherein the modulation is ligand independent repression.

40. A method for modulating the expression of an exogenous gene in a cell containing:

- 15 1) a chimeric protein according to claim 1 and
2) a DNA construct comprising the exogenous gene under the control of a response element with which the chimeric protein interacts, wherein said response element controls expression of the exogenous gene, said method comprising administering to the cell an effective amount of an exogenous ligand for at least one functional unit of the chimeric protein.

20 41. The method according to claim 40 wherein the modulation is ligand independent activation.

42. The method according to claim 40 wherein the modulation is ligand independent repression.

25 43. A method for modulating the expression of one or more genes in a subject organism containing an endogenous response element, wherein said response element controls expression of one or more genes

said method comprising introducing a chimeric protein according to claim 1 to the subject that interacts with said response element, thereby modulating expression of the gene(s) independent of the presence of ligand for the chimeric protein.

30 44. The method according to claim 43 wherein the chimeric protein is encoded by an inducible DNA construct and the modulating comprises inducing expression of the gene(s).

45. A method for modulating the expression of one or more genes in a subject organism containing an endogenous response element controlling expression of one or more genes,

35

said method comprising introducing to the subject a chimeric protein according to claim 1 that interacts with the response element, thereby modulating expression of the gene(s) dependent on the presence of endogenous ligand therefor.

5 46. The method according to claim 45 wherein the chimeric protein is encoded by an inducible DNA construct and the modulating comprises inducing expression of the gene(s).

47. A method for modulating the expression of one or more genes in a subject organism containing:

1) a chimeric protein according to claim 1, and

10 2) an endogenous response element controlling expression of the one or more genes, wherein the chimeric protein interacts with the response element,

said method comprising introducing to the subject an exogenous ligand for the chimeric protein, thereby modulating expression of the gene(s) dependent on the presence of the exogenous ligand.

15 48. A method for modulating the expression of one or more genes in a subject organism containing:

1) a chimeric protein according to claim 1, and

2) an endogenous response element controlling expression of the one or more genes, wherein the chimeric protein interacts with the response element,

20 said method comprising introducing to the subject an exogenous ligand for the chimeric protein, thereby modulating expression of the gene(s) dependent on the presence of the exogenous ligand.

49. A method for modulating the expression of one or more genes in a subject organism containing:

a chimeric protein according to claim 1, and

an exogenous ligand for the chimeric protein,

25 said method comprising introducing to the subject an endogenous response element controlling expression of the one or more genes, wherein the chimeric protein interacts with the response element, thereby modulating expression of the gene(s) dependent on the presence of the exogenous ligand.

30 50. A method for modulating the expression of one or more genes in a subject organism containing a chimeric protein according to claim 1,

wherein said method comprises introducing to the subject an exogenous response element controlling expression of the one or more genes,

wherein the response element interacts with the chimeric protein thereby modulating expression of the gene(s) independent of the presence of ligand for the chimeric protein.

51. A method for modulating the expression of one or more genes in a subject organism containing an exogenous response element controlling expression of the one or more genes,

said method comprising introducing to the subject a chimeric protein according to claim 1 that interacts with the response element, thereby modulating expression of the gene(s) independent of the presence of ligand for the chimeric protein.

52. An isolated protein crystal suitable for x-ray diffraction analysis comprising a purified chimeric protein according to claim 1.

53. The protein crystal according to claim 52 further comprising a ligand bound to the purified chimeric protein so as to form a chimeric protein-ligand complex.

54. The protein crystal according to claim 53 further comprising a nucleic acid construct being a putative response element for the complex.

55. A set of x-ray diffraction crystal coordinates obtained by x-ray diffraction of the isolated protein crystal according to claim 52.

56. A set of x-ray diffraction crystal coordinates obtained by x-ray diffraction of the protein crystal according to claim 54.

57. A method for identifying a potential ligand for a member of the steroid/thyroid hormone receptor superfamily, said method comprising:

creating a three-dimensional structure of a chimeric protein as defined by the x-ray diffraction coordinates according to claim 55,

employing said three-dimensional structure to design or select the potential ligand;

synthesizing the potential ligand; and

contacting the potential ligand with the chimeric protein in the presence of the response element with which the chimeric protein interacts operatively linked to a marker gene under conditions suitable for causing expression of the marker gene to determine the ability of said potential ligand to transactivate expression of the marker gene.

58. A method for identifying compounds that modulate formation of a functional entity in a cell containing:
a chimeric protein according to claim 1, and

a response element with which the chimeric protein interacts operatively linked to a marker protein,

said method comprising contacting the cell with a test compound under conditions suitable to cause the chimeric protein to transactivate expression of the marker gene, and

5 determining the amount of the marker protein produced as compared with the amount produced in the absence of the test compound,

wherein a difference in the amount of marker gene expressed indicates a modulation of formation of the functional entity due to the presence of the test compound.

10 59. The method according to claim 58 wherein the amount of marker protein expressed is increased, indicating that the test compound facilitates formation of the functional entity.

60. The method according to claim 58 wherein the amount of marker protein expressed is decreased, indicating that the test compound represses formation of the functional entity.




FIGURE 1




FIGURE 2A




FIGURE 2B




FIGURE 3




FIGURE 4A




FIGURE 4B




FIGURE 5A




FIGURE 5B




FIGURE 5C




FIGURE 6

FIGURE 7A



Native
Dimer

FIGURE 7B




Disorganized

FIGURE 7C




Endodimer



Trimer



Tetramer



Oligomer

FIGURE 7D

FIGURE 7E

FIGURE 7F




FIGURE 8

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number
WO 01/036447 A3

(51) International Patent Classification⁷: **G01N 33/53**,
C12Q 1/68, C07H 21/04

(74) Agent: **REITER, Stephen, E.**; Gray Cary Ware & Freidenrich LLP, Suite 1600, 4365 Executive Drive, San Diego, CA 92121-2189 (US).

(21) International Application Number: PCT/US00/41224

(22) International Filing Date: 17 October 2000 (17.10.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/421,971 20 October 1999 (20.10.1999) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/421,971 (CON)
Filed on 20 October 1999 (20.10.1999)

(71) Applicant (for all designated States except US): **THE SALK INSTITUTE FOR BIOLOGICAL STUDIES** [US/US]; 10010 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GAGE, Fred, H.** [US/US]; 6668 Caminito Hermitage, La Jolla, CA 92037 (US). **SUHR, Steven, T.** [US/US]; 8860 Via La Jolla Drive, La Jolla, CA 92037 (US). **GIL, Elad, B.** [US/US]; 141 Charles St. #3, Boston, MA 02114 (US). **SENUT, Marie-Claude, C.** [US/US]; 8860 Via La Jolla Drive, La Jolla, CA 92121-2189 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
15 August 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HORMONE RECEPTOR FUNCTIONAL ENTITIES AND METHODS OF THEIR USE

(57) Abstract: The invention provides chimeric proteins having at least two functional protein units, each containing the dimerization domain of a member of the steroid/thyroid hormone nuclear receptor superfamily. The chimeric proteins can fold under crystallization conditions to form functional entities. The functional entities optionally contain a novel flexible peptide linker of variable lengths between at least two of the protein units. In a preferred embodiment, the linker is designed to be increased in increments of 12 amino acids each to aid in preparation of variant chimeric proteins. The DNA binding characteristics of the invention functional entities differ from those of wild-type complexes formed between "monomeric" receptors and their binding partners. Some functional entities, e.g. dimers expressed as fusion proteins, transactivate responsive promoters in a manner similar to wild-type complexes, while others do not promote transactivation and function instead essentially as constitutive repressors. The invention further provides nucleotide sequences encoding the invention chimeric proteins, cells containing such nucleotide sequences, and methods for using the invention chimeric proteins to modulate expression of one or more exogenous genes in a subject organism. In addition, isolated protein crystals suitable for x-ray diffraction analysis and methods for obtaining putative ligands for the invention chimeric proteins are provided.

WO 01/036447 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/41224

A. CLASSIFICATION OF SUBJECT MATTERIPC(7) : G01N 33/53; C12Q 1/68; C07H 21/04
US CL : 435/6, 7.8, 320.1, 325; 536/23.5; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHEDMinimum documentation searched (classification system followed by classification symbols)
U.S. : 435/6, 7.8, 320.1, 325; 536/23.5; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EAST MEDLINE BIOSIS EMBASE CAPLUS**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,830,462 A (CRABTREE et al.) 03 November 1998, see entire document.	1-60
Y	US 5,599,904 A (EVANS et al.) 04 February 1997, see entire document.	1-60
Y	WO 93/11235 A3 (THE SALK INSTITUTE FOR BIOLOGICAL STUDIES) 10 June 1993, see entire document.	1-60

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier application or patent published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

30 May 2002 (30.05.2002)

Date of mailing of the international search report

01 JUL 2002

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Joseph F. Murphy

Telephone No. 703-308-0196